Market Outlook

By 2035, the U.S. Multiplex Point-of-Care Testing Devices Market is expected to reach approximately USD 1.78 billion, growing at a CAGR of 12.67% during the forecast period 2026–2035. The market is estimated at approximately USD 0.54 billion in 2025, with historical analysis covering 2021–2024. Values in this report are expressed in USD billions.

For the purpose of this report, the market includes multiplex point-of-care analyzers and the proprietary cartridges, cassettes, test units, and associated consumables required to simultaneously detect or differentiate multiple clinically relevant targets near the patient. It includes molecular and antigen-based multiplex testing used in hospitals, emergency departments, urgent care centers, physician offices, ambulatory clinics, retail healthcare locations, and selected home settings. High-throughput centralized laboratory syndromic panels, conventional single-target rapid tests, and laboratory-developed tests outside the point-of-care workflow are excluded.

The U.S. market is transitioning from a rapid-test environment historically dominated by single-analyte influenza, streptococcal, pregnancy, glucose, and COVID-19 products toward a more clinically useful multiplex model. Respiratory symptoms are a particularly strong use case because influenza A, influenza B, SARS-CoV-2, RSV, and other respiratory infections frequently present with overlapping symptoms yet can require different treatment, isolation, referral, or monitoring decisions. Multiplex platforms allow clinicians to obtain more actionable information from a single specimen and patient encounter rather than relying on sequential testing.

This clinical proposition has become economically important as testing decentralizes. The United States has more than 6,000 hospitals and approximately 35.7 million annual hospital admissions, while the urgent care sector has expanded to more than 15,000 centers and manages more than 185 million patient encounters annually. These care settings increasingly require diagnostic platforms that can operate with limited laboratory infrastructure, provide results within the patient visit, connect with electronic health records, and support treatment or disposition decisions without sending specimens to a central laboratory.

The respiratory disease burden creates a substantial recurring testing pool. During the 2024–2025 influenza season, an estimated 51 million Americans experienced influenza illness, approximately 23 million sought outpatient medical care, and around 710,000 influenza-related hospitalizations occurred. RSV is also estimated to cause roughly 110,000–180,000 hospitalizations annually among U.S. adults aged 50 years and older. In parallel, the U.S. recorded more than 2.2 million reported cases of chlamydia, gonorrhea, and syphilis during 2024, supporting the longer-term expansion of multiplex POC testing beyond respiratory disease into sexual health and other syndromic applications.

Historical market revenue is estimated to have increased from approximately USD 0.29 billion in 2021 to USD 0.35 billion in 2022, USD 0.42 billion in 2023, and USD 0.48 billion in 2024, before reaching approximately USD 0.54 billion in 2025. Expansion during this period reflected broader acceptance of decentralized molecular testing, conversion of emergency-use respiratory testing into more durable commercial pathways, growth of combination COVID-19/influenza/RSV assays, and installation of cartridge-based molecular systems outside traditional microbiology laboratories.

From 2026 through 2035, growth will increasingly be determined by whether multiplex testing can move from seasonal respiratory use into a broader decentralized diagnostic platform. The strongest suppliers will be those capable of expanding menus while preserving short turnaround time, CLIA-waived usability, low hands-on time, connectivity, quality control, cartridge availability, and an acceptable cost per actionable diagnosis.

 

Introduction

According to the U.S. Multiplex Point-of-Care Testing Devices Market Report, multiplex POC diagnostics are becoming an increasingly strategic component of U.S. decentralized care because they address a fundamental clinical problem: many patients present with syndromes rather than known pathogens. Fever, cough, sore throat, dysuria, genital symptoms, gastrointestinal symptoms, or nonspecific systemic illness may have multiple etiologies that cannot be reliably differentiated through symptoms alone.

Traditional diagnostic pathways frequently involve either empirical treatment, sequential rapid testing, or specimen referral to a central laboratory. Each approach has limitations. Empirical treatment can contribute to unnecessary antimicrobial use. Sequential testing adds consumable cost and clinical waiting time. Central laboratory testing can provide high analytical performance but may not return results quickly enough to influence decisions during a short outpatient encounter.

Multiplex POC devices change this workflow by integrating sample preparation, amplification or antigen detection, target differentiation, interpretation, and reporting into a compact system. Molecular platforms can provide laboratory-like nucleic acid detection within a decentralized workflow, while multiplex immunoassays and lateral-flow formats offer faster, lower-cost alternatives for selected applications.

The commercial opportunity therefore extends beyond test substitution. Multiplex platforms compete on the value of information produced during a single patient encounter. In an emergency department, a result can support isolation, antiviral use, admission, or discharge decisions. In urgent care, it can reduce repeat testing and help clinicians differentiate respiratory infections before the patient leaves. In sexual health, same-visit molecular results can reduce loss to follow-up and accelerate targeted treatment.

U.S. purchasing behavior is also changing. Health systems increasingly evaluate POC platforms across instrument cost, cartridge price, test-menu breadth, staffing requirements, turnaround time, analyzer utilization, quality-control burden, connectivity, service support, and reimbursement. A nominally inexpensive assay may produce poor economics if it requires several sequential tests, additional labor, or follow-up calls. Conversely, a higher-priced multiplex cartridge may be economically acceptable if it replaces multiple individual tests and materially changes treatment decisions.

The next decade of market development will therefore be driven by platform economics. Manufacturers that build a broad menu around a common analyzer can create recurring cartridge revenue while giving provider systems a stronger reason to standardize instruments across emergency departments, urgent care sites, physician offices, and satellite clinics.

 

Key Market Drivers: What’s Fueling the U.S. Multiplex Point-of-Care Testing Devices Market Boom?

The first major driver is the large U.S. respiratory testing burden. Influenza, COVID-19, RSV, and other respiratory infections create millions of healthcare encounters every year, particularly during fall and winter. The 2024–2025 influenza season alone generated approximately 23 million outpatient medical visits. Because respiratory pathogens frequently produce similar symptoms, multiplex testing has direct clinical utility by differentiating diseases that may otherwise be indistinguishable at presentation.

A second driver is the expansion of urgent care and decentralized outpatient medicine. The U.S. has more than 15,000 urgent care centers, and the sector handles more than 185 million patient encounters annually. Urgent care operators compete partly on convenience and the ability to resolve episodes of care during one visit. Sending a respiratory specimen to an external laboratory and contacting the patient later weakens this model. Fast multiplex testing therefore aligns closely with urgent care workflow economics.

A third growth driver is the increasing availability of CLIA-waived molecular tests. Historically, molecular diagnostics were concentrated in moderate- and high-complexity laboratories because of sample preparation, amplification, contamination control, and interpretation requirements. Integrated cartridge-based systems have progressively automated these processes. Recent FDA clearances and CLIA waiver decisions across several multiplex respiratory and sexual-health platforms demonstrate that sophisticated molecular testing can increasingly be performed by non-laboratory personnel in decentralized settings.

A fourth driver is antimicrobial stewardship. Viral and bacterial illnesses frequently overlap clinically. Access to rapid diagnostic information can help clinicians avoid unnecessary antibiotics, select antiviral therapy when indicated, and determine whether additional confirmatory testing is required. This capability is especially relevant for health systems attempting to standardize antimicrobial stewardship across emergency departments, urgent care networks, pediatric practices, and ambulatory clinics.

The fifth driver is hospital interest in operational efficiency. Emergency departments face significant pressure around length of stay, bed availability, isolation-room utilization, and clinician throughput. A multiplex result available during the decision window can be more valuable than a broader central-laboratory panel reported after the disposition decision has already been made. Procurement committees increasingly evaluate whether POC diagnostics can reduce unnecessary testing, facilitate patient cohorting, shorten waiting time, or prevent inappropriate admissions.

A sixth driver is the growth of menu expansion beyond respiratory disease. Sexual-health testing represents an important opportunity because the U.S. continues to report more than 2.2 million cases of chlamydia, gonorrhea, and syphilis annually. Rapid multiplex molecular tests capable of differentiating sexually transmitted infections can support same-visit treatment and reduce patient loss to follow-up. Future platforms are also targeting gastrointestinal infections, febrile illness, antimicrobial resistance markers, and other syndromic applications.

A seventh driver is technology convergence. Modern POC systems increasingly combine microfluidics, automated extraction, nucleic acid amplification, optical or electrochemical detection, embedded software, cloud connectivity, and automated result interpretation. These advances are reducing the operational distinction between traditional laboratory analyzers and point-of-care devices.

The eighth driver is recurring-revenue economics for manufacturers. Unlike standalone disposable tests, installed POC analyzers can generate recurring proprietary cartridge consumption. Once a hospital network or urgent care chain standardizes on a platform, instrument placement creates opportunities for respiratory, sexual-health, and other assays to run on the same installed base. This razor-and-blade economics makes menu breadth and installed-base penetration strategically important.

 

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation in the U.S. multiplex POC testing market is moving toward a combination of greater multiplexing, shorter turnaround time, lower hands-on complexity, menu expansion, and digital integration. Analytical performance remains essential, but commercial differentiation increasingly depends on how smoothly the technology fits into real clinical workflows.

Compact molecular PCR systems are one of the most important innovation areas. Platforms capable of performing automated nucleic acid extraction, amplification, detection, and interpretation in approximately 15–30 minutes are narrowing the historical performance gap between centralized molecular laboratories and point-of-care environments. Respiratory combinations detecting influenza A, influenza B, RSV, and SARS-CoV-2 have become a central competitive battleground.

Syndromic menu design is also evolving. The earlier generation of multiplex POC testing focused primarily on two- or three-target combinations. Newer systems increasingly support four-target respiratory assays, broader respiratory panels, respiratory/sore-throat combinations, and sexual-health assays capable of detecting several organisms from a single patient sample.

Miniaturization is creating another commercial opportunity. Earlier molecular systems required meaningful benchtop space, dedicated power, and relatively controlled workflows. New platforms are becoming smaller, easier to operate, and more suitable for urgent care treatment rooms, physician offices, retail healthcare locations, decentralized hospital units, and mobile clinical environments.

Manufacturers are also focusing on random-access workflow. Seasonal respiratory surges create highly variable demand. An analyzer that processes only one cartridge at a time can become a bottleneck during peak periods. Suppliers are therefore competing through multi-module configurations, scalable instrument placements, short cycle times, and networked analyzer fleets that allow high-volume operators to expand capacity without purchasing conventional laboratory automation.

Connectivity has become another purchasing criterion. U.S. health systems increasingly expect POC devices to integrate with electronic medical records, laboratory information systems, middleware, operator-management software, and quality-control programs. Automatic result transfer reduces transcription errors and helps health systems supervise dozens or hundreds of decentralized instruments from a central laboratory or POC coordination team.

The next innovation cycle will likely move toward multiplex platforms that answer clinical questions rather than simply detect organisms. Host-response biomarkers, bacterial-versus-viral differentiation, resistance markers, quantitative measurements, and decision-support algorithms could become progressively more important. If these capabilities can be delivered with waived-test simplicity, they could materially expand the value of multiplex POC testing beyond respiratory seasonality.

 

Segmentation Insights

The U.S. Multiplex Point-of-Care Testing Devices Market is segmented on the basis of product type, clinical application, technology, end user, and geography.

 

By Product Type

Multiplex Assay Cartridges, Cassettes and Test Kits

Multiplex assay cartridges and test units represent the largest revenue component of the market, accounting for an estimated USD 0.34 billion in 2025. Their leadership reflects recurring utilization after instruments are installed. Unlike capital equipment, cartridges generate revenue every time a patient is tested, making procedure volume, respiratory season intensity, assay pricing, and menu breadth the principal economic drivers.

Molecular cartridges command particularly strong value because they integrate sample preparation, amplification, target-specific detection, controls, and result interpretation into a disposable unit. Respiratory cartridges currently represent the largest installed-base opportunity.

Multiplex Analyzer Systems

Analyzer systems represented an estimated USD 0.14 billion in 2025. This category includes compact PCR analyzers, cartridge readers, immunoassay readers, modular molecular systems, and other dedicated point-of-care instruments. Analyzer revenue is influenced by new site installations, replacements, fleet expansion, rental and reagent-placement models, and conversion from competing platforms.

Instrument pricing alone does not determine competitive success. Buyers increasingly evaluate the total economics of an analyzer across throughput, assay menu, service requirements, footprint, operator complexity, connectivity, and proprietary consumable cost.

Software, Connectivity and Associated Accessories

Software, connectivity, accessories, controls, and device-related workflow components represented approximately USD 0.06 billion in 2025. Although smaller than assay revenue, this segment is strategically important as healthcare systems centralize oversight of decentralized testing programs.

Vendor-neutral middleware, operator lockout, quality-control tracking, remote diagnostics, cybersecurity, connectivity to laboratory information systems, and automatic EMR reporting increasingly influence systemwide purchasing decisions.

 

By Clinical Application

Respiratory Infectious Disease Testing

Respiratory infectious disease is the dominant application and represented approximately USD 0.35 billion in 2025. Influenza A/B, SARS-CoV-2, RSV, and broader respiratory syndromes produce substantial seasonal testing volumes across emergency departments, urgent care centers, pediatric clinics, primary care practices, hospitals, and retail healthcare locations.

The key commercial advantage of multiplexing is simultaneous differentiation. During respiratory season, symptom-based diagnosis alone is unreliable. A single multiplex test can influence antiviral therapy, infection-control precautions, return-to-work guidance, and decisions regarding additional diagnostic workup.

Sexual Health and STI Testing

Sexual-health testing represents one of the strongest opportunities for diversification beyond respiratory diagnostics. Chlamydia, gonorrhea, Mycoplasma genitalium, and other infections can produce overlapping symptoms or remain asymptomatic. More than 2.2 million cases of major reportable STIs were recorded in the United States in 2024, illustrating the size of the diagnostic pool.

Same-visit molecular results are particularly valuable in sexual-health clinics, emergency departments, student health facilities, community health centers, and physician offices because delayed laboratory results can lead to loss to follow-up or empirical multidrug treatment.

Gastrointestinal and Enteric Disease Testing

Gastrointestinal applications remain smaller at the POC level than centralized syndromic panels but represent an emerging opportunity. Patients with diarrhea, vomiting, or abdominal symptoms can have viral, bacterial, or parasitic etiologies that are difficult to differentiate clinically.

Commercial growth will depend on whether manufacturers can reduce panel complexity and cost sufficiently for outpatient environments. Focused multiplex panels targeting the pathogens most likely to change immediate treatment could prove more commercially attractive than very broad laboratory-style panels.

Febrile Illness and Host-Response Testing

Febrile illness and bacterial-versus-viral differentiation represent another emerging segment. The objective is increasingly to determine whether a patient is likely to benefit from antibacterial therapy rather than simply identify one pathogen.

Host-response and multi-biomarker approaches could become useful in urgent care, emergency medicine, pediatrics, and primary care, particularly as antimicrobial stewardship becomes more closely tied to clinical quality.

Other Multiplex Applications

Other applications include sore-throat panels, women’s health, selected hospital-acquired infections, resistance-marker detection, tropical or travel-associated infections, and future decentralized syndromic assays. These applications currently represent a modest share of revenue but are strategically important because they can increase instrument utilization outside peak respiratory months.

 

By Technology

PCR and Other Nucleic Acid Amplification Technologies

PCR and related molecular amplification technologies dominate the market by value, accounting for an estimated USD 0.31 billion in 2025. Their leadership is driven by high sensitivity, target specificity, automated cartridge formats, and growing availability of CLIA-waived systems.

Real-time RT-PCR is particularly important for respiratory multiplexing. Molecular systems are likely to retain premium positioning where clinical decisions require greater analytical sensitivity than conventional antigen testing can provide.

Isothermal Molecular Amplification

Isothermal amplification technologies avoid conventional thermal cycling and can enable smaller, faster, or lower-power devices. Approaches such as loop-mediated amplification and other proprietary amplification chemistries can potentially reduce instrument complexity.

Their long-term opportunity will depend on achieving robust multiplex capability without sacrificing sensitivity, specificity, ease of manufacturing, or assay stability.

Multiplex Antigen Immunoassays and Lateral Flow

Multiplex antigen testing is a major volume-oriented category, particularly for influenza/COVID-19 combinations and respiratory screening. The technology benefits from low cost, fast results, minimal instrument requirements, and familiarity among healthcare workers.

Its principal limitation is analytical sensitivity relative to molecular testing. The market is therefore evolving into a tiered structure in which antigen multiplex tests serve high-throughput, cost-sensitive use cases while molecular platforms address situations where higher sensitivity or treatment-critical differentiation is required.

Microfluidic and Electrochemical Detection

Microfluidic systems integrate very small fluid volumes, reaction chambers, amplification processes, and detection elements within compact cartridges. Electrochemical detection can further reduce dependence on complex optical hardware.

These technologies have strong potential in sexual-health testing and next-generation molecular POC devices because they can support compact system architectures and automated sample-to-answer workflows.

Emerging Biosensor and Integrated Detection Technologies

Emerging technologies include digital amplification, biosensors, novel optical detection, multiplex immunochemistry, nanomaterials, and hybrid molecular-immunoassay systems. The commercial threshold for adoption will remain demanding: new technologies must deliver not only analytical novelty but also manufacturability, stability, simple operation, rapid results, regulatory clearance, and competitive cost per test.

 

By End User

Hospitals and Emergency Departments

Hospitals remain the largest end-user segment, generating an estimated USD 0.20 billion in 2025. Emergency departments represent a particularly important POC setting because diagnostic information must often be available before admission, discharge, isolation, or treatment decisions are finalized.

Large integrated delivery networks may deploy multiple analyzers across emergency departments, pediatric units, obstetric services, outpatient clinics, and satellite facilities. Enterprise contracts therefore create significant recurring assay opportunities for manufacturers.

Urgent Care and Retail Healthcare

Urgent care and retail healthcare represented approximately USD 0.15 billion in 2025 and constitute one of the fastest-expanding end-user categories. More than 15,000 U.S. urgent care centers collectively manage over 185 million patient encounters annually, creating substantial potential for rapid respiratory multiplex testing.

These buyers generally prioritize low hands-on time, CLIA-waived status, compact footprint, predictable cartridge availability, short turnaround time, and a reimbursement model that works at outpatient visit economics.

Physician Offices and Primary Care Clinics

Primary care, pediatric, family medicine, internal medicine, and physician-owned clinics represented approximately USD 0.08 billion in 2025. Adoption in these sites remains more price-sensitive because test volumes may be lower than in hospitals or large urgent care chains.

Platforms that can run multiple clinically relevant assays on one small analyzer are likely to perform better than systems dedicated to a single seasonal application.

Ambulatory and Specialty Clinics

Sexual-health clinics, community health centers, student health services, ambulatory infectious-disease practices, women’s health clinics, and other specialty sites represented approximately USD 0.06 billion in 2025.

Same-visit testing is particularly valuable where patient follow-up is uncertain. Molecular STI testing and focused infectious-disease panels can therefore provide clinical value beyond simple turnaround-time improvement.

Home and Consumer-Directed Testing

The home and consumer-directed segment represented approximately USD 0.05 billion in 2025 but has strong long-term optionality. FDA authorization of combination influenza/COVID-19 tests demonstrates growing regulatory acceptance of multiplex self-testing.

The future market could move beyond visually interpreted lateral-flow products toward instrument-assisted or digitally interpreted home diagnostics. However, pricing, reimbursement, consumer willingness to pay, sample collection accuracy, and linkage to clinical care will determine the speed of adoption.

 

Regional Insights: Where the Market is Growing Fastest

Regional demand for multiplex point-of-care testing is shaped less by disease prevalence alone than by the combination of population scale, patient-access models, provider density, seasonal respiratory patterns, retail health penetration, hospital purchasing structures, and laboratory staffing economics.

The South is estimated to represent the largest regional market in 2025, while the West is expected to deliver the fastest percentage growth through 2035. The Northeast remains important for premium molecular adoption and academic evidence generation, while the Midwest provides a stable hospital, urgent care, and community-clinic testing base.

South

The South represented an estimated USD 0.19 billion in 2025, making it the largest U.S. regional market. Revenue could approach approximately USD 0.64 billion by 2035 as multiplex testing expands across hospital systems, urgent care networks, physician practices, and community healthcare facilities.

Texas is the region’s most important state market. Its population scale, large metropolitan areas, extensive hospital infrastructure, numerous urgent care operators, and decentralized suburban healthcare model create strong demand for rapid respiratory testing. Houston, Dallas–Fort Worth, Austin, and San Antonio are particularly attractive markets for analyzer placements and enterprise diagnostic contracts.

Florida represents another major demand center. Its large population aged 65 and older increases exposure to severe influenza and RSV outcomes, while the state’s dense urgent care, outpatient, hospital, and senior-care infrastructure creates a substantial seasonal respiratory testing opportunity.

Georgia and North Carolina are increasingly important due to fast population growth, expanding metropolitan healthcare systems, and significant investment in ambulatory care. Atlanta, Charlotte, Raleigh-Durham, and other growth markets support adoption of compact molecular platforms across hospital-affiliated urgent care and physician networks.

Virginia and Maryland have sophisticated health systems and dense suburban healthcare markets surrounding Washington, D.C., Baltimore, Richmond, Northern Virginia, and Hampton Roads. These areas are well suited to connected POC networks in which decentralized analyzers are managed through centralized quality and laboratory oversight.

Tennessee benefits from major healthcare organizations and strong provider networks centered around Nashville, Memphis, Knoxville, and Chattanooga. Multiplex testing fits both hospital emergency care and rapidly expanding outpatient delivery models.

South Carolina, Kentucky, Alabama, Louisiana, Mississippi, Arkansas, Oklahoma, and West Virginia provide a different opportunity. Many communities in these states have longer distances to reference laboratories and more limited specialist access, increasing the practical value of obtaining an actionable result during the initial clinical encounter. Cost sensitivity is higher, making cartridge economics and broad analyzer utility especially important.

Delaware is smaller in absolute market size but benefits from dense East Coast healthcare access and proximity to major Mid-Atlantic provider networks. Washington, D.C. is commercially relevant despite its small geographic footprint because of its concentration of major health systems, academic institutions, government-related healthcare facilities, and highly mobile population.

The South is likely to maintain regional leadership because it combines large patient volumes with rapid suburban expansion and significant urgent care penetration. Respiratory multiplex systems will remain the largest revenue pool, but sexual-health and focused syndromic applications could contribute increasingly to analyzer utilization.

West

The West represented an estimated USD 0.13 billion in 2025 and is expected to become the fastest-growing U.S. region, potentially reaching approximately USD 0.50 billion by 2035. The region benefits from technology adoption, strong integrated delivery networks, retail healthcare expansion, medtech innovation, and a willingness among large provider systems to redesign diagnostic workflows.

California is the largest Western state market and one of the most important multiplex POC markets nationally. Its population size, academic health systems, biotechnology industry, large urgent care footprint, community clinic networks, and diverse infectious-disease testing requirements create demand across both premium molecular and lower-cost antigen platforms.

Health systems in California also tend to place strong emphasis on connectivity, operator management, cybersecurity, antimicrobial stewardship, and standardized multi-site testing. This makes the state an attractive launch market for device companies offering integrated hardware, cartridges, informatics, and centralized fleet management.

Arizona and Nevada are high-growth opportunities because of rapid population expansion and large retirement communities. Phoenix, Tucson, Las Vegas, and surrounding suburban markets support significant respiratory testing volumes, particularly among older adults at higher risk of influenza and RSV complications.

Washington and Oregon have sophisticated integrated provider networks and high adoption of digitally connected healthcare. These states are particularly attractive for molecular systems positioned around clinical workflow, antimicrobial stewardship, and standardized ambulatory diagnostics.

Colorado and Utah combine population growth, strong health systems, research-oriented provider organizations, and expanding outpatient medicine. Denver, Salt Lake City, and surrounding metropolitan corridors provide favorable environments for analyzer placement.

New Mexico, Idaho, Montana, and Wyoming present smaller absolute markets but important decentralized-testing opportunities. Rural travel distances and limited access to conventional laboratory infrastructure can increase the clinical value of sample-to-answer testing in community hospitals, outpatient clinics, tribal health services, and regional care networks.

Alaska represents a particularly distinctive use case because geography can create long specimen-transport times. Compact molecular technologies that deliver definitive results locally can offer meaningful operational value in remote healthcare settings. Hawaii similarly benefits from island-based healthcare logistics and the value of rapid local testing, although its overall market size is comparatively modest.

The West will likely gain market share as multiplex diagnostics become more digitally integrated and expand beyond conventional respiratory testing. California’s technology ecosystem and the region’s strong integrated health networks make it an important proving ground for next-generation decentralized molecular platforms.

Northeast

The Northeast accounted for an estimated USD 0.12 billion in 2025 and could reach approximately USD 0.35 billion by 2035. The region has high diagnostic sophistication, dense specialist availability, strong academic medical centers, and mature central-laboratory infrastructure.

These characteristics create a demanding competitive environment. Multiplex POC systems must demonstrate a clear workflow advantage because many providers already have access to rapid centralized molecular testing. Successful POC products therefore tend to be positioned where immediate clinical decision-making materially benefits from a result at the bedside or within the outpatient visit.

New York represents the region’s largest state market. New York City’s hospital systems, urgent care density, high-volume emergency departments, and large outpatient networks support substantial multiplex respiratory testing. Upstate health systems also present opportunities where regional laboratory transport can increase turnaround time.

Pennsylvania has a large hospital base and substantial metropolitan markets around Philadelphia and Pittsburgh. Integrated health systems can support enterprise POC deployments across emergency departments, urgent care sites, pediatric services, and community clinics.

Massachusetts is disproportionately influential because of its concentration of academic medical centers, biotechnology companies, clinical research institutions, and early-adopter physicians. Although smaller than New York or Pennsylvania by population, Massachusetts can influence national adoption through clinical validation and purchasing decisions by recognized health systems.

New Jersey combines dense population, strong hospital systems, pharmaceutical-sector presence, and extensive outpatient care. Multiplex respiratory and sexual-health testing are particularly relevant in high-throughput suburban healthcare settings.

Connecticut and Rhode Island have compact geographies and highly integrated referral networks, supporting centralized device-management models with multiple POC analyzers distributed across sites.

Maine, New Hampshire, and Vermont are smaller markets but offer important use cases for community hospitals and rural outpatient facilities where rapid local diagnostics can reduce specimen-referral delays.

The Northeast will remain one of the most strategically important regions for clinical evidence, premium molecular adoption, and platform evaluation. Growth will be steadier than in the West because of market maturity, but revenue per installed analyzer can be attractive in high-volume hospital and urgent care systems.

Midwest

The Midwest represented approximately USD 0.10 billion in 2025 and could reach roughly USD 0.29 billion by 2035. The region provides a stable mix of large academic hospitals, community healthcare systems, suburban urgent care networks, rural facilities, and established laboratory infrastructure.

Illinois is the largest Midwestern state opportunity, led by the Chicago metropolitan market. High hospital density and a large outpatient healthcare ecosystem provide strong potential for respiratory multiplex adoption.

Ohio has extensive health system infrastructure across Cleveland, Columbus, Cincinnati, and other metropolitan areas. Its large academic and community hospital networks make it a significant market for standardized molecular POC deployments.

Michigan provides strong demand through Detroit and other regional healthcare systems, while its seasonal respiratory burden supports recurring influenza, RSV, and COVID-19 testing.

Minnesota is strategically important because of its sophisticated healthcare delivery environment and medical technology ecosystem. Provider systems in the state often emphasize evidence-based procurement, interoperability, and workflow economics.

Indiana and Wisconsin offer stable demand across hospital-affiliated outpatient networks, urgent care centers, and physician practices. Manufacturers that combine dependable service with predictable cartridge economics can build durable positions in these markets.

Missouri has meaningful demand around St. Louis and Kansas City, while Iowa and Kansas provide opportunities for community hospitals, regional care networks, and decentralized rural testing.

Nebraska, North Dakota, and South Dakota are smaller in revenue terms but demonstrate the operational value of point-of-care molecular testing. Where specimens would otherwise travel considerable distances to centralized laboratories, same-site results can materially improve clinical workflow.

The Midwest is unlikely to outgrow the West or South, but it remains an attractive market for companies emphasizing reliability, analyzer utilization, standardized contracting, and broad geographic service capability.

 

Key Market Players

The competitive landscape of the U.S. Multiplex Point-of-Care Testing Devices Market is becoming more fragmented and innovation-driven. Large diagnostics companies benefit from established sales organizations, hospital contracts, installed analyzer bases, regulatory expertise, and manufacturing scale. At the same time, specialized molecular diagnostic companies are entering the market with compact systems designed specifically around decentralized testing.

Competition increasingly centers on the total platform rather than a single assay. A supplier with a 15-minute respiratory test may gain an initial instrument placement, but long-term account retention depends on whether the platform subsequently supports additional respiratory, sexual-health, throat, or other syndromic tests. Menu breadth raises analyzer utilization and improves the economic justification for health systems.

Some of the key companies and strategically relevant participants in the U.S. market include bioMérieux/BioFire Diagnostics; Roche Diagnostics; Cepheid, a Danaher operating company; Abbott Laboratories; QuidelOrtho; Visby Medical; Nuclein; DiaSorin Molecular; LEX Diagnostics; Baebies; Pfizer/Lucira; ACON Laboratories; Healgen Scientific; Sekisui Diagnostics; Princeton BioMeditech; CorDx; Maxim Biomedical; Access Bio; Lumos Diagnostics; binx health; Becton, Dickinson and Company; Autonomous Medical Devices; and Thermo Fisher Scientific.

bioMérieux has strengthened its decentralized molecular position through the BIOFIRE SPOTFIRE platform and respiratory/sore-throat syndromic menu. Roche competes through the cobas Liat ecosystem, which combines compact PCR instrumentation with respiratory and sexual-health assays. Cepheid benefits from the large GeneXpert installed base and Xpert Xpress menu, giving it significant hospital and near-patient molecular testing visibility.

Visby Medical represents an important specialist competitor because its single-use molecular architecture challenges the conventional distinction between disposable rapid tests and analyzer-based PCR. Nuclein, DiaSorin, LEX Diagnostics, Baebies, and other emerging companies are contributing to a new generation of compact molecular systems with faster workflows and simplified operation.

Antigen-focused companies remain relevant because not every clinical situation requires molecular sensitivity. ACON, Healgen, Sekisui, CorDx, Access Bio, Princeton BioMeditech, and other rapid-test companies compete in high-volume respiratory testing where speed, low cost, and minimal instrumentation can outweigh the benefits of molecular platforms.

Market share through 2035 will be determined by FDA clearances, CLIA-waived status, menu breadth, instrument throughput, cartridge manufacturing capacity, clinical accuracy, connectivity, reimbursement, channel access, and the ability to demonstrate workflow savings. Companies relying on one seasonal respiratory assay will be more exposed than suppliers capable of increasing analyzer utilization across the full calendar year.

 

Recent Developments

Recent developments in the U.S. market show that multiplex point-of-care testing is moving from pandemic-era emergency deployment into a more durable FDA-cleared diagnostic category.

In 2024, the FDA cleared the BIOFIRE SPOTFIRE Respiratory/Sore Throat Panel and subsequently the Respiratory/Sore Throat Panel Mini, strengthening bioMérieux’s position in decentralized syndromic molecular testing. CLIA waiver activity around the SPOTFIRE platform further expanded its relevance to near-patient environments.

Another important milestone occurred when Nuclein’s DASH SARS-CoV-2 & Flu A/B Test received traditional U.S. marketing authorization and CLIA-waived status in late 2024. The development illustrated the continued transition of combination respiratory molecular testing away from temporary pandemic authorization structures.

During 2025, the FDA granted traditional marketing authorization to Cepheid’s Xpert Xpress CoV-2/Flu/RSV plus, while its GeneXpert Xpress system also received CLIA-waived categorization for the multiplex respiratory assay. This expanded the durability of Cepheid’s respiratory portfolio beyond the COVID-19 emergency period.

Visby Medical’s Respiratory Health Test received U.S. authorization and CLIA-waived status during 2025, strengthening the competitive position of compact single-use molecular testing. The product category is strategically important because it removes or substantially reduces the need for conventional installed analyzer hardware.

Roche expanded the cobas Liat franchise through respiratory and sexual-health assays. CLIA waiver activity around cobas Liat SARS-CoV-2 & Influenza A/B, CT/NG, and CT/NG/MG illustrates how POC molecular platforms are extending beyond respiratory disease. Sexual-health menu expansion is particularly significant because it can improve analyzer utilization outside the winter respiratory season.

In late 2025, DiaSorin Molecular’s LIAISON NES FLU A/B, RSV & COVID-19 assay received U.S. clearance, adding another compact molecular competitor capable of detecting four major respiratory pathogens from a single nasal specimen.

The innovation cycle continued in 2026. LEX Diagnostics’ VELO Respiratory Test received U.S. clearance and CLIA-waived status, adding competitive pressure in rapid multiplex PCR. Baebies received CLIA waiver for a FINDER influenza A/B and SARS-CoV-2 assay, while additional respiratory devices from established and emerging diagnostic companies continued to enter the waived-testing pipeline.

Antigen-based multiplexing is also advancing. New respiratory combination products incorporating influenza A/B, COVID-19, and RSV illustrate the movement toward broader multi-pathogen testing in simple rapid-test formats.

These developments indicate that the competitive question is shifting from whether multiplex POC testing can be performed reliably to which platform architecture will dominate particular care settings. Large hospitals may favor modular high-throughput systems with strong connectivity, urgent care operators may prioritize fast CLIA-waived molecular analyzers, and cost-sensitive settings may continue to favor multiplex antigen tests.

 

Conclusion

The U.S. Multiplex Point-of-Care Testing Devices Market Size & Share is positioned for strong expansion from an estimated USD 0.54 billion in 2025 to approximately USD 1.78 billion by 2035, representing a 12.67% CAGR during the 2026–2035 forecast period. Historical market revenue increased from approximately USD 0.29 billion in 2021 to USD 0.48 billion in 2024 as molecular testing became progressively more decentralized and respiratory multiplexing moved into routine clinical workflows.

Respiratory infectious disease will remain the largest near-term revenue pool, supported by tens of millions of annual influenza illnesses, significant RSV morbidity, continuing SARS-CoV-2 circulation, and the inability to reliably distinguish these diseases from symptoms alone. However, the market’s long-term investment case depends increasingly on menu expansion into sexual health, febrile illness, sore-throat syndromes, gastrointestinal disease, resistance markers, and other applications that increase analyzer utilization outside respiratory season.

The most commercially attractive platforms will combine rapid sample-to-answer performance, high analytical accuracy, CLIA-waived operation, minimal hands-on time, strong connectivity, scalable throughput, and a broad proprietary cartridge menu. Instrument placement without menu expansion will become progressively less defensible as healthcare systems consolidate suppliers and demand stronger returns from POC infrastructure.

Hospitals will remain the largest end users, but urgent care represents one of the most strategically important growth channels. More than 15,000 U.S. urgent care centers collectively manage over 185 million patient visits annually, creating an addressable clinical environment built around same-visit diagnosis and treatment.

Geographically, the South is expected to remain the largest regional market, supported by Texas, Florida, North Carolina, Georgia, Virginia, Tennessee, and other growing healthcare markets. The West is projected to grow fastest, led by California and supported by Arizona, Washington, Colorado, Nevada, and Utah. The Northeast will remain critical for premium molecular adoption and clinical evidence generation, while the Midwest will provide durable demand across hospital and community healthcare networks.

For manufacturers, investors, hospital laboratories, urgent care operators, distributors, and other clients evaluating this market, the central issue is not simply whether multiplex testing volumes will rise. The more important strategic questions are which assays will meaningfully alter same-visit clinical decisions, which device architectures can scale economically across decentralized sites, which platforms can secure CLIA-waived menu breadth, and which manufacturers can convert instrument placements into sustainable recurring cartridge revenue.

The companies best positioned through 2035 will be those that treat multiplex POC testing as an integrated clinical workflow rather than an isolated diagnostic product. Accuracy remains the entry requirement; competitive leadership will increasingly depend on speed, menu breadth, instrument utilization, decentralized usability, connectivity, manufacturing reliability, reimbursement alignment, and measurable improvement in the economics of the patient encounter.

 

TABLE OF CONTENT

1. U.S. Multiplex Point-of-Care Testing Devices Market: Market Introduction & Context

1.1. Market Definition
1.2. Scope of the Study
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. Market Sizing, Bottom-Up Validation & Forecasting Models
1.3.6. Data Triangulation and Final Report Publishing
1.4. Key Assumptions
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. Multiplex Point-of-Care Testing Device Manufacturers
1.6.2. Molecular Assay, Reagent and Cartridge Suppliers
1.6.3. Microfluidic, Biosensor and Diagnostic Component Suppliers
1.6.4. Hospitals, Emergency Departments and Integrated Delivery Networks
1.6.5. Urgent Care, Retail Health and Physician Office Networks
1.6.6. Clinical Laboratories and Point-of-Care Testing Coordinators
1.6.7. Distributors, Group Purchasing Organizations and Channel Partners
1.6.8. CMS, FDA, Payers and Public Health Agencies

What this section provides: This section defines the U.S. multiplex point-of-care testing devices market boundary, study scope, methodology, assumptions, inclusion/exclusion criteria, and stakeholder ecosystem so clients understand how market revenues and forecasts are measured and validated.

2. U.S. Multiplex Point-of-Care Testing Devices Market: Executive Summary

2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.6. Forecast Outlook, 2026–2035
2.7. U.S. Market Size, 2021–2035 (US$ Billion)
2.8. Growth Opportunity Heatmap
2.9. High-Growth Opportunity Areas
2.9.1. Multiplex Respiratory Molecular Testing
2.9.2. CLIA-Waived Molecular Platforms
2.9.3. Same-Visit STI Testing
2.9.4. Urgent Care and Retail Health Deployment
2.9.5. Broader Syndromic Point-of-Care Testing
2.9.6. Multi-Assay Analyzer Menu Expansion

What this section provides: This section gives decision-makers a concise view of market size, historical development, forecast growth, competitive intensity, technology direction, fastest-growing applications, and priority commercial opportunities through 2035.

3. U.S. Multiplex Point-of-Care Testing Devices Market: Market Dynamics & Outlook

3.1. Drivers and Their Impact Analysis
3.1.1. High U.S. Respiratory Infectious Disease Testing Burden
3.1.2. Growing Need for Same-Visit Clinical Decision-Making
3.1.3. Expansion of Urgent Care and Decentralized Outpatient Testing
3.1.4. Increasing Availability of CLIA-Waived Molecular Platforms
3.1.5. Demand for Influenza A/B, RSV and SARS-CoV-2 Differentiation
3.1.6. Antimicrobial Stewardship and Reduction of Empirical Treatment
3.1.7. Expansion of Multiplex Testing Beyond Respiratory Disease
3.1.8. Installed-Base and Recurring Cartridge Revenue Economics
3.2. Restraints and Their Impact Analysis
3.2.1. High Cost Per Molecular Multiplex Test
3.2.2. Reimbursement Variability Across Testing Settings
3.2.3. Seasonal Variability in Respiratory Testing Volumes
3.2.4. Competition from Lower-Cost Single-Target Rapid Tests
3.2.5. Limited Assay Menus on Emerging Point-of-Care Platforms
3.2.6. Quality-Control and Operator-Competency Requirements
3.3. Opportunities and Their Impact Analysis
3.3.1. Expansion of Four-Target and Broad Respiratory Panels
3.3.2. Same-Visit Multiplex STI Testing
3.3.3. Gastrointestinal and Enteric POC Panels
3.3.4. Host-Response and Bacterial-versus-Viral Testing
3.3.5. Rural and Community Healthcare Testing
3.3.6. Home and Consumer-Directed Multiplex Diagnostics
3.3.7. Multi-Menu Analyzer Utilization Beyond Respiratory Season
3.3.8. Connected POC Fleets and Centralized Quality Oversight
3.4. Challenges and Their Impact Analysis
3.4.1. Maintaining Multiplex Sensitivity at Short Turnaround Times
3.4.2. Cartridge Manufacturing and Supply Reliability
3.4.3. Decentralized Device Connectivity and Cybersecurity
3.4.4. Reimbursement versus Test-Cost Economics
3.4.5. Managing False Positive and False Negative Clinical Consequences
3.5. Patent & Innovation Analysis, 2021–2025
3.6. Clinical Workflow Economics Analysis
3.7. Point-of-Care versus Central Laboratory Turnaround-Time Analysis
3.8. Analyzer Placement and Recurring Cartridge Economics
3.9. Hospital and Urgent Care Procurement Behavior Analysis

What this section provides: This section explains the clinical, economic, regulatory, workflow and commercial forces shaping U.S. multiplex point-of-care testing demand and helps clients assess both addressable opportunity and market-entry risk.

4. U.S. Multiplex Point-of-Care Testing Devices Market: Market Environment & Industry Analysis

4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers
4.2.3. Bargaining Power of Suppliers
4.2.4. Threat of Substitution
4.2.5. Competitive Rivalry
4.3. Multiplex Test Pricing Trend Analysis, 2025–2035
4.4. Analyzer and Cartridge Value Chain Analysis
4.5. Supply Chain Analysis
4.5.1. Reagents and Enzymes
4.5.2. Primers, Probes and Antibodies
4.5.3. Microfluidic Components
4.5.4. Plastic Cartridges and Cassettes
4.5.5. Optical and Electronic Components
4.5.6. Contract Manufacturing and Final Assembly
4.6. Point-of-Care Connectivity and Digitalization Landscape
4.7. Application & Innovation Landscape
4.8. FDA Regulatory Framework Analysis
4.8.1. 510(k) Pathway
4.8.2. De Novo Pathway
4.8.3. Emergency Use Authorization Legacy
4.8.4. CLIA Waiver Requirements
4.8.5. Over-the-Counter and Home-Use Authorization Considerations
4.9. CLIA Regulatory Landscape and Testing Complexity
4.10. CMS Reimbursement and Coverage Landscape
4.11. CPT Coding and Diagnostic Reimbursement Dynamics
4.12. Public Health Testing and Federal Program Influence
4.13. Import/Export Restrictions, Tariffs and Component Availability
4.14. Impact of Geopolitical and Supply-Chain Disruption
4.15. Health-System Value Analysis and Vendor Selection Framework
4.15.1. Test Accuracy
4.15.2. Turnaround Time
4.15.3. Cost Per Reportable Result
4.15.4. Analyzer Throughput
4.15.5. Assay Menu Breadth
4.15.6. Connectivity
4.15.7. Cartridge Availability
4.15.8. Service and Technical Support

What this section provides: This section provides a comprehensive view of regulation, CLIA status, reimbursement, pricing, supply chain, diagnostic technology, digital connectivity, and healthcare procurement criteria shaping commercial success in the U.S. market.

5. U.S. Multiplex Point-of-Care Testing Devices Market – By Product Type

5.1. Overview
5.1.1. Segment Share Analysis, By Product Type, 2025 & 2035 (%)
5.1.2. Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
5.2. Multiplex Assay Cartridges, Cassettes and Test Kits
5.2.1. Molecular Assay Cartridges
5.2.2. Antigen Multiplex Test Cassettes
5.2.3. Disposable Sample-to-Answer Molecular Test Units
5.2.4. Other Multiplex Consumables
5.3. Multiplex Analyzer Systems
5.3.1. Single-Module Molecular Analyzers
5.3.2. Multi-Module Molecular Analyzers
5.3.3. Immunoassay and Lateral-Flow Readers
5.3.4. Portable and Handheld Multiplex Analyzers
5.4. Software and Connectivity Solutions
5.4.1. Device Management Software
5.4.2. LIS/EMR Connectivity
5.4.3. Remote Quality-Control Platforms
5.4.4. Operator Management and Compliance Software
5.5. Accessories, Controls and Supporting Components
5.5.1. Quality-Control Materials
5.5.2. Sample Collection Accessories
5.5.3. Calibration and Maintenance Products
5.5.4. Other Supporting Components

What this section provides: This section identifies the product categories contributing to U.S. market revenue and assesses how proprietary consumables, analyzer placements, connectivity solutions, and recurring test utilization will shape revenue growth through 2035.

6. U.S. Multiplex Point-of-Care Testing Devices Market – By Clinical Application

6.1. Overview
6.1.1. Segment Share Analysis, By Clinical Application, 2025 & 2035 (%)
6.1.2. Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
6.2. Respiratory Infectious Disease Testing
6.2.1. Influenza A & Influenza B
6.2.2. SARS-CoV-2
6.2.3. Respiratory Syncytial Virus
6.2.4. Influenza/COVID-19 Combination Testing
6.2.5. Influenza/COVID-19/RSV Multiplex Testing
6.2.6. Broader Respiratory Syndromic Panels
6.3. Sexual Health and Sexually Transmitted Infection Testing
6.3.1. Chlamydia trachomatis
6.3.2. Neisseria gonorrhoeae
6.3.3. Mycoplasma genitalium
6.3.4. Trichomonas vaginalis
6.3.5. Multi-Pathogen STI Panels
6.4. Gastrointestinal and Enteric Disease Testing
6.4.1. Viral Gastrointestinal Pathogens
6.4.2. Bacterial Gastrointestinal Pathogens
6.4.3. Focused Enteric Multiplex Panels
6.5. Febrile Illness and Host-Response Testing
6.5.1. Bacterial-versus-Viral Differentiation
6.5.2. Inflammatory Biomarker Combinations
6.5.3. Acute Febrile Syndrome Testing
6.6. Other Clinical Applications
6.6.1. Sore Throat and Pharyngitis Testing
6.6.2. Women’s Health Testing
6.6.3. Antimicrobial Resistance Marker Detection
6.6.4. Travel-Associated and Emerging Infectious Diseases
6.6.5. Other Syndromic Applications

What this section provides: This section helps clients quantify demand by clinical use case and identify applications where multiplex testing offers the strongest combination of testing volume, treatment impact, workflow value, and long-term menu-expansion potential.

7. U.S. Multiplex Point-of-Care Testing Devices Market – By Technology

7.1. Overview
7.1.1. Segment Share Analysis, By Technology, 2025 & 2035 (%)
7.1.2. Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
7.2. PCR and Real-Time RT-PCR
7.2.1. Cartridge-Based PCR
7.2.2. Rapid RT-PCR
7.2.3. Fully Integrated Sample-to-Answer PCR
7.3. Isothermal Nucleic Acid Amplification
7.3.1. Loop-Mediated Isothermal Amplification
7.3.2. Recombinase-Based Amplification
7.3.3. Other Proprietary Isothermal Technologies
7.4. Multiplex Antigen Immunoassays and Lateral Flow
7.4.1. Instrument-Free Lateral Flow Tests
7.4.2. Reader-Assisted Immunoassays
7.4.3. Digital Immunoassay Platforms
7.5. Microfluidic and Electrochemical Detection
7.5.1. Microfluidic Molecular Platforms
7.5.2. Electrochemical Biosensing
7.5.3. Lab-on-Chip Platforms
7.6. Emerging Biosensor and Integrated Detection Technologies
7.6.1. Digital Molecular Detection
7.6.2. Optical Biosensors
7.6.3. Nanomaterial-Enabled Detection
7.6.4. Hybrid Molecular-Immunoassay Platforms

What this section provides: This section evaluates the diagnostic technologies competing for adoption in decentralized U.S. testing and identifies which platforms are best positioned around speed, sensitivity, multiplexing capability, instrument simplicity, and cost per result.

8. U.S. Multiplex Point-of-Care Testing Devices Market – By End User

8.1. Overview
8.1.1. Segment Share Analysis, By End User, 2025 & 2035 (%)
8.1.2. Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
8.2. Hospitals and Emergency Departments
8.2.1. Academic Medical Centers
8.2.2. Community Hospitals
8.2.3. Emergency Departments
8.2.4. Pediatric Hospitals
8.2.5. Hospital Satellite Facilities
8.3. Urgent Care and Retail Healthcare
8.3.1. Independent Urgent Care Centers
8.3.2. Health-System-Owned Urgent Care Networks
8.3.3. Retail Clinics
8.3.4. Pharmacy-Based Testing Sites
8.4. Physician Offices and Primary Care Clinics
8.4.1. Family Medicine
8.4.2. Internal Medicine
8.4.3. Pediatrics
8.4.4. Primary Care Group Practices
8.5. Ambulatory, Specialty and Community Clinics
8.5.1. Sexual Health Clinics
8.5.2. Community Health Centers
8.5.3. Student Health Centers
8.5.4. Women’s Health Clinics
8.5.5. Infectious Disease Clinics
8.6. Home and Consumer-Directed Testing
8.6.1. OTC Multiplex Rapid Tests
8.6.2. Digitally Interpreted Home Tests
8.6.3. Home Molecular Testing Platforms

What this section provides: This section identifies which U.S. care settings will drive analyzer placement and recurring assay utilization and evaluates how throughput requirements, staffing, reimbursement, patient volume, and testing complexity differ by customer type.

9. U.S. Multiplex Point-of-Care Testing Devices Market – By Geography

9.1. Introduction
9.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
9.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
9.1.3. Regional Infectious Disease Testing Burden Analysis
9.1.4. Regional Hospital, Urgent Care and Ambulatory Infrastructure Analysis
9.1.5. Regional CLIA-Waived Testing Adoption Analysis
9.1.6. Regional Reimbursement and Procurement Dynamics
9.1.7. Regional Analyzer Placement and Cartridge Utilization Trends
9.2. West Region
9.2.1. Regional Overview & Trends
9.2.2. West Region Key Manufacturers, Distribution and Procurement Ecosystem
9.2.3. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
9.2.4. West Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.5. West Region Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.2.6. West Region Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
9.2.7. West Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.8. West Region Testing Volume, Installed Base and Adoption Hotspot Analysis
9.2.9. California
9.2.9.1. Overview
9.2.9.2. California Market Size and Forecast, By Product Type, 2021–2035
9.2.9.3. California Market Size and Forecast, By Clinical Application, 2021–2035
9.2.9.4. California Market Size and Forecast, By Technology, 2021–2035
9.2.9.5. California Market Size and Forecast, By End User, 2021–2035
9.2.10. Washington
9.2.10.1. Overview
9.2.10.2. Washington Market Size and Forecast, By Product Type, 2021–2035
9.2.10.3. Washington Market Size and Forecast, By Clinical Application, 2021–2035
9.2.10.4. Washington Market Size and Forecast, By Technology, 2021–2035
9.2.10.5. Washington Market Size and Forecast, By End User, 2021–2035
9.2.11. Arizona
9.2.11.1. Overview
9.2.11.2. Arizona Market Size and Forecast, By Product Type, 2021–2035
9.2.11.3. Arizona Market Size and Forecast, By Clinical Application, 2021–2035
9.2.11.4. Arizona Market Size and Forecast, By Technology, 2021–2035
9.2.11.5. Arizona Market Size and Forecast, By End User, 2021–2035
9.2.12. Colorado
9.2.12.1. Overview
9.2.12.2. Colorado Market Size and Forecast, By Product Type, 2021–2035
9.2.12.3. Colorado Market Size and Forecast, By Clinical Application, 2021–2035
9.2.12.4. Colorado Market Size and Forecast, By Technology, 2021–2035
9.2.12.5. Colorado Market Size and Forecast, By End User, 2021–2035
9.2.13. Oregon
9.2.13.1. Overview
9.2.13.2. Oregon Market Size and Forecast, By Product Type, 2021–2035
9.2.13.3. Oregon Market Size and Forecast, By Clinical Application, 2021–2035
9.2.13.4. Oregon Market Size and Forecast, By Technology, 2021–2035
9.2.13.5. Oregon Market Size and Forecast, By End User, 2021–2035
9.2.14. Utah
9.2.14.1. Overview
9.2.14.2. Utah Market Size and Forecast, By Product Type, 2021–2035
9.2.14.3. Utah Market Size and Forecast, By Clinical Application, 2021–2035
9.2.14.4. Utah Market Size and Forecast, By Technology, 2021–2035
9.2.14.5. Utah Market Size and Forecast, By End User, 2021–2035
9.2.15. Nevada
9.2.15.1. Overview
9.2.15.2. Nevada Market Size and Forecast, By Product Type, 2021–2035
9.2.15.3. Nevada Market Size and Forecast, By Clinical Application, 2021–2035
9.2.15.4. Nevada Market Size and Forecast, By Technology, 2021–2035
9.2.15.5. Nevada Market Size and Forecast, By End User, 2021–2035
9.2.16. New Mexico
9.2.16.1. Overview
9.2.16.2. New Mexico Market Size and Forecast, By Product Type, 2021–2035
9.2.16.3. New Mexico Market Size and Forecast, By Clinical Application, 2021–2035
9.2.16.4. New Mexico Market Size and Forecast, By Technology, 2021–2035
9.2.16.5. New Mexico Market Size and Forecast, By End User, 2021–2035
9.2.17. Idaho
9.2.17.1. Overview
9.2.17.2. Idaho Market Size and Forecast, By Product Type, 2021–2035
9.2.17.3. Idaho Market Size and Forecast, By Clinical Application, 2021–2035
9.2.17.4. Idaho Market Size and Forecast, By Technology, 2021–2035
9.2.17.5. Idaho Market Size and Forecast, By End User, 2021–2035
9.2.18. Montana
9.2.18.1. Overview
9.2.18.2. Montana Market Size and Forecast, By Product Type, 2021–2035
9.2.18.3. Montana Market Size and Forecast, By Clinical Application, 2021–2035
9.2.18.4. Montana Market Size and Forecast, By Technology, 2021–2035
9.2.18.5. Montana Market Size and Forecast, By End User, 2021–2035
9.2.19. Wyoming
9.2.19.1. Overview
9.2.19.2. Wyoming Market Size and Forecast, By Product Type, 2021–2035
9.2.19.3. Wyoming Market Size and Forecast, By Clinical Application, 2021–2035
9.2.19.4. Wyoming Market Size and Forecast, By Technology, 2021–2035
9.2.19.5. Wyoming Market Size and Forecast, By End User, 2021–2035
9.2.20. Alaska
9.2.20.1. Overview
9.2.20.2. Alaska Market Size and Forecast, By Product Type, 2021–2035
9.2.20.3. Alaska Market Size and Forecast, By Clinical Application, 2021–2035
9.2.20.4. Alaska Market Size and Forecast, By Technology, 2021–2035
9.2.20.5. Alaska Market Size and Forecast, By End User, 2021–2035
9.2.21. Hawaii
9.2.21.1. Overview
9.2.21.2. Hawaii Market Size and Forecast, By Product Type, 2021–2035
9.2.21.3. Hawaii Market Size and Forecast, By Clinical Application, 2021–2035
9.2.21.4. Hawaii Market Size and Forecast, By Technology, 2021–2035
9.2.21.5. Hawaii Market Size and Forecast, By End User, 2021–2035
9.3. Northeast Region
9.3.1. Regional Overview & Trends
9.3.2. Northeast Region Key Manufacturers, Distribution and Procurement Ecosystem
9.3.3. Northeast Region Market Size and Forecast, By State, 2021–2035
9.3.4. Northeast Region Market Size and Forecast, By Product Type, 2021–2035
9.3.5. Northeast Region Market Size and Forecast, By Clinical Application, 2021–2035
9.3.6. Northeast Region Market Size and Forecast, By Technology, 2021–2035
9.3.7. Northeast Region Market Size and Forecast, By End User, 2021–2035
9.3.8. Northeast Region Testing Volume, Installed Base and Adoption Hotspot Analysis
9.3.9. New York
9.3.9.1. Overview
9.3.9.2. New York Market Size and Forecast, By Product Type, 2021–2035
9.3.9.3. New York Market Size and Forecast, By Clinical Application, 2021–2035
9.3.9.4. New York Market Size and Forecast, By Technology, 2021–2035
9.3.9.5. New York Market Size and Forecast, By End User, 2021–2035
9.3.10. Massachusetts
9.3.10.1. Overview
9.3.10.2. Massachusetts Market Size and Forecast, By Product Type, 2021–2035
9.3.10.3. Massachusetts Market Size and Forecast, By Clinical Application, 2021–2035
9.3.10.4. Massachusetts Market Size and Forecast, By Technology, 2021–2035
9.3.10.5. Massachusetts Market Size and Forecast, By End User, 2021–2035
9.3.11. New Jersey
9.3.11.1. Overview
9.3.11.2. New Jersey Market Size and Forecast, By Product Type, 2021–2035
9.3.11.3. New Jersey Market Size and Forecast, By Clinical Application, 2021–2035
9.3.11.4. New Jersey Market Size and Forecast, By Technology, 2021–2035
9.3.11.5. New Jersey Market Size and Forecast, By End User, 2021–2035
9.3.12. Pennsylvania
9.3.12.1. Overview
9.3.12.2. Pennsylvania Market Size and Forecast, By Product Type, 2021–2035
9.3.12.3. Pennsylvania Market Size and Forecast, By Clinical Application, 2021–2035
9.3.12.4. Pennsylvania Market Size and Forecast, By Technology, 2021–2035
9.3.12.5. Pennsylvania Market Size and Forecast, By End User, 2021–2035
9.3.13. Connecticut
9.3.13.1. Overview
9.3.13.2. Connecticut Market Size and Forecast, By Product Type, 2021–2035
9.3.13.3. Connecticut Market Size and Forecast, By Clinical Application, 2021–2035
9.3.13.4. Connecticut Market Size and Forecast, By Technology, 2021–2035
9.3.13.5. Connecticut Market Size and Forecast, By End User, 2021–2035
9.3.14. Maine
9.3.14.1. Overview
9.3.14.2. Maine Market Size and Forecast, By Product Type, 2021–2035
9.3.14.3. Maine Market Size and Forecast, By Clinical Application, 2021–2035
9.3.14.4. Maine Market Size and Forecast, By Technology, 2021–2035
9.3.14.5. Maine Market Size and Forecast, By End User, 2021–2035
9.3.15. Vermont
9.3.15.1. Overview
9.3.15.2. Vermont Market Size and Forecast, By Product Type, 2021–2035
9.3.15.3. Vermont Market Size and Forecast, By Clinical Application, 2021–2035
9.3.15.4. Vermont Market Size and Forecast, By Technology, 2021–2035
9.3.15.5. Vermont Market Size and Forecast, By End User, 2021–2035
9.3.16. New Hampshire
9.3.16.1. Overview
9.3.16.2. New Hampshire Market Size and Forecast, By Product Type, 2021–2035
9.3.16.3. New Hampshire Market Size and Forecast, By Clinical Application, 2021–2035
9.3.16.4. New Hampshire Market Size and Forecast, By Technology, 2021–2035
9.3.16.5. New Hampshire Market Size and Forecast, By End User, 2021–2035
9.3.17. Rhode Island
9.3.17.1. Overview
9.3.17.2. Rhode Island Market Size and Forecast, By Product Type, 2021–2035
9.3.17.3. Rhode Island Market Size and Forecast, By Clinical Application, 2021–2035
9.3.17.4. Rhode Island Market Size and Forecast, By Technology, 2021–2035
9.3.17.5. Rhode Island Market Size and Forecast, By End User, 2021–2035
9.3.18. Delaware
9.3.18.1. Overview
9.3.18.2. Delaware Market Size and Forecast, By Product Type, 2021–2035
9.3.18.3. Delaware Market Size and Forecast, By Clinical Application, 2021–2035
9.3.18.4. Delaware Market Size and Forecast, By Technology, 2021–2035
9.3.18.5. Delaware Market Size and Forecast, By End User, 2021–2035
9.4. South Region
9.4.1. Regional Overview & Trends
9.4.2. South Region Key Manufacturers, Distribution and Procurement Ecosystem
9.4.3. South Region Market Size and Forecast, By State, 2021–2035
9.4.4. South Region Market Size and Forecast, By Product Type, 2021–2035
9.4.5. South Region Market Size and Forecast, By Clinical Application, 2021–2035
9.4.6. South Region Market Size and Forecast, By Technology, 2021–2035
9.4.7. South Region Market Size and Forecast, By End User, 2021–2035
9.4.8. South Region Testing Volume, Installed Base and Adoption Hotspot Analysis
9.4.9. Texas
9.4.9.1. Overview
9.4.9.2. Texas Market Size and Forecast, By Product Type, 2021–2035
9.4.9.3. Texas Market Size and Forecast, By Clinical Application, 2021–2035
9.4.9.4. Texas Market Size and Forecast, By Technology, 2021–2035
9.4.9.5. Texas Market Size and Forecast, By End User, 2021–2035
9.4.10. Florida
9.4.10.1. Overview
9.4.10.2. Florida Market Size and Forecast, By Product Type, 2021–2035
9.4.10.3. Florida Market Size and Forecast, By Clinical Application, 2021–2035
9.4.10.4. Florida Market Size and Forecast, By Technology, 2021–2035
9.4.10.5. Florida Market Size and Forecast, By End User, 2021–2035
9.4.11. Georgia
9.4.11.1. Overview
9.4.11.2. Georgia Market Size and Forecast, By Product Type, 2021–2035
9.4.11.3. Georgia Market Size and Forecast, By Clinical Application, 2021–2035
9.4.11.4. Georgia Market Size and Forecast, By Technology, 2021–2035
9.4.11.5. Georgia Market Size and Forecast, By End User, 2021–2035
9.4.12. North Carolina
9.4.12.1. Overview
9.4.12.2. North Carolina Market Size and Forecast, By Product Type, 2021–2035
9.4.12.3. North Carolina Market Size and Forecast, By Clinical Application, 2021–2035
9.4.12.4. North Carolina Market Size and Forecast, By Technology, 2021–2035
9.4.12.5. North Carolina Market Size and Forecast, By End User, 2021–2035
9.4.13. Tennessee
9.4.13.1. Overview
9.4.13.2. Tennessee Market Size and Forecast, By Product Type, 2021–2035
9.4.13.3. Tennessee Market Size and Forecast, By Clinical Application, 2021–2035
9.4.13.4. Tennessee Market Size and Forecast, By Technology, 2021–2035
9.4.13.5. Tennessee Market Size and Forecast, By End User, 2021–2035
9.4.14. South Carolina
9.4.14.1. Overview
9.4.14.2. South Carolina Market Size and Forecast, By Product Type, 2021–2035
9.4.14.3. South Carolina Market Size and Forecast, By Clinical Application, 2021–2035
9.4.14.4. South Carolina Market Size and Forecast, By Technology, 2021–2035
9.4.14.5. South Carolina Market Size and Forecast, By End User, 2021–2035
9.4.15. Alabama
9.4.15.1. Overview
9.4.15.2. Alabama Market Size and Forecast, By Product Type, 2021–2035
9.4.15.3. Alabama Market Size and Forecast, By Clinical Application, 2021–2035
9.4.15.4. Alabama Market Size and Forecast, By Technology, 2021–2035
9.4.15.5. Alabama Market Size and Forecast, By End User, 2021–2035
9.4.16. Mississippi
9.4.16.1. Overview
9.4.16.2. Mississippi Market Size and Forecast, By Product Type, 2021–2035
9.4.16.3. Mississippi Market Size and Forecast, By Clinical Application, 2021–2035
9.4.16.4. Mississippi Market Size and Forecast, By Technology, 2021–2035
9.4.16.5. Mississippi Market Size and Forecast, By End User, 2021–2035
9.4.17. Louisiana
9.4.17.1. Overview
9.4.17.2. Louisiana Market Size and Forecast, By Product Type, 2021–2035
9.4.17.3. Louisiana Market Size and Forecast, By Clinical Application, 2021–2035
9.4.17.4. Louisiana Market Size and Forecast, By Technology, 2021–2035
9.4.17.5. Louisiana Market Size and Forecast, By End User, 2021–2035
9.4.18. Arkansas
9.4.18.1. Overview
9.4.18.2. Arkansas Market Size and Forecast, By Product Type, 2021–2035
9.4.18.3. Arkansas Market Size and Forecast, By Clinical Application, 2021–2035
9.4.18.4. Arkansas Market Size and Forecast, By Technology, 2021–2035
9.4.18.5. Arkansas Market Size and Forecast, By End User, 2021–2035
9.4.19. Kentucky
9.4.19.1. Overview
9.4.19.2. Kentucky Market Size and Forecast, By Product Type, 2021–2035
9.4.19.3. Kentucky Market Size and Forecast, By Clinical Application, 2021–2035
9.4.19.4. Kentucky Market Size and Forecast, By Technology, 2021–2035
9.4.19.5. Kentucky Market Size and Forecast, By End User, 2021–2035
9.4.20. Oklahoma
9.4.20.1. Overview
9.4.20.2. Oklahoma Market Size and Forecast, By Product Type, 2021–2035
9.4.20.3. Oklahoma Market Size and Forecast, By Clinical Application, 2021–2035
9.4.20.4. Oklahoma Market Size and Forecast, By Technology, 2021–2035
9.4.20.5. Oklahoma Market Size and Forecast, By End User, 2021–2035
9.4.21. Virginia
9.4.21.1. Overview
9.4.21.2. Virginia Market Size and Forecast, By Product Type, 2021–2035
9.4.21.3. Virginia Market Size and Forecast, By Clinical Application, 2021–2035
9.4.21.4. Virginia Market Size and Forecast, By Technology, 2021–2035
9.4.21.5. Virginia Market Size and Forecast, By End User, 2021–2035
9.4.22. Maryland
9.4.22.1. Overview
9.4.22.2. Maryland Market Size and Forecast, By Product Type, 2021–2035
9.4.22.3. Maryland Market Size and Forecast, By Clinical Application, 2021–2035
9.4.22.4. Maryland Market Size and Forecast, By Technology, 2021–2035
9.4.22.5. Maryland Market Size and Forecast, By End User, 2021–2035
9.4.23. West Virginia
9.4.23.1. Overview
9.4.23.2. West Virginia Market Size and Forecast, By Product Type, 2021–2035
9.4.23.3. West Virginia Market Size and Forecast, By Clinical Application, 2021–2035
9.4.23.4. West Virginia Market Size and Forecast, By Technology, 2021–2035
9.4.23.5. West Virginia Market Size and Forecast, By End User, 2021–2035
9.5. Midwest Region
9.5.1. Regional Overview & Trends
9.5.2. Midwest Region Key Manufacturers, Distribution and Procurement Ecosystem
9.5.3. Midwest Region Market Size and Forecast, By State, 2021–2035
9.5.4. Midwest Region Market Size and Forecast, By Product Type, 2021–2035
9.5.5. Midwest Region Market Size and Forecast, By Clinical Application, 2021–2035
9.5.6. Midwest Region Market Size and Forecast, By Technology, 2021–2035
9.5.7. Midwest Region Market Size and Forecast, By End User, 2021–2035
9.5.8. Midwest Region Testing Volume, Installed Base and Adoption Hotspot Analysis
9.5.9. Illinois
9.5.9.1. Overview
9.5.9.2. Illinois Market Size and Forecast, By Product Type, 2021–2035
9.5.9.3. Illinois Market Size and Forecast, By Clinical Application, 2021–2035
9.5.9.4. Illinois Market Size and Forecast, By Technology, 2021–2035
9.5.9.5. Illinois Market Size and Forecast, By End User, 2021–2035
9.5.10. Ohio
9.5.10.1. Overview
9.5.10.2. Ohio Market Size and Forecast, By Product Type, 2021–2035
9.5.10.3. Ohio Market Size and Forecast, By Clinical Application, 2021–2035
9.5.10.4. Ohio Market Size and Forecast, By Technology, 2021–2035
9.5.10.5. Ohio Market Size and Forecast, By End User, 2021–2035
9.5.11. Michigan
9.5.11.1. Overview
9.5.11.2. Michigan Market Size and Forecast, By Product Type, 2021–2035
9.5.11.3. Michigan Market Size and Forecast, By Clinical Application, 2021–2035
9.5.11.4. Michigan Market Size and Forecast, By Technology, 2021–2035
9.5.11.5. Michigan Market Size and Forecast, By End User, 2021–2035
9.5.12. Minnesota
9.5.12.1. Overview
9.5.12.2. Minnesota Market Size and Forecast, By Product Type, 2021–2035
9.5.12.3. Minnesota Market Size and Forecast, By Clinical Application, 2021–2035
9.5.12.4. Minnesota Market Size and Forecast, By Technology, 2021–2035
9.5.12.5. Minnesota Market Size and Forecast, By End User, 2021–2035
9.5.13. Indiana
9.5.13.1. Overview
9.5.13.2. Indiana Market Size and Forecast, By Product Type, 2021–2035
9.5.13.3. Indiana Market Size and Forecast, By Clinical Application, 2021–2035
9.5.13.4. Indiana Market Size and Forecast, By Technology, 2021–2035
9.5.13.5. Indiana Market Size and Forecast, By End User, 2021–2035
9.5.14. Wisconsin
9.5.14.1. Overview
9.5.14.2. Wisconsin Market Size and Forecast, By Product Type, 2021–2035
9.5.14.3. Wisconsin Market Size and Forecast, By Clinical Application, 2021–2035
9.5.14.4. Wisconsin Market Size and Forecast, By Technology, 2021–2035
9.5.14.5. Wisconsin Market Size and Forecast, By End User, 2021–2035
9.5.15. Missouri
9.5.15.1. Overview
9.5.15.2. Missouri Market Size and Forecast, By Product Type, 2021–2035
9.5.15.3. Missouri Market Size and Forecast, By Clinical Application, 2021–2035
9.5.15.4. Missouri Market Size and Forecast, By Technology, 2021–2035
9.5.15.5. Missouri Market Size and Forecast, By End User, 2021–2035
9.5.16. Iowa
9.5.16.1. Overview
9.5.16.2. Iowa Market Size and Forecast, By Product Type, 2021–2035
9.5.16.3. Iowa Market Size and Forecast, By Clinical Application, 2021–2035
9.5.16.4. Iowa Market Size and Forecast, By Technology, 2021–2035
9.5.16.5. Iowa Market Size and Forecast, By End User, 2021–2035
9.5.17. Kansas
9.5.17.1. Overview
9.5.17.2. Kansas Market Size and Forecast, By Product Type, 2021–2035
9.5.17.3. Kansas Market Size and Forecast, By Clinical Application, 2021–2035
9.5.17.4. Kansas Market Size and Forecast, By Technology, 2021–2035
9.5.17.5. Kansas Market Size and Forecast, By End User, 2021–2035
9.5.18. Nebraska
9.5.18.1. Overview
9.5.18.2. Nebraska Market Size and Forecast, By Product Type, 2021–2035
9.5.18.3. Nebraska Market Size and Forecast, By Clinical Application, 2021–2035
9.5.18.4. Nebraska Market Size and Forecast, By Technology, 2021–2035
9.5.18.5. Nebraska Market Size and Forecast, By End User, 2021–2035
9.5.19. North Dakota
9.5.19.1. Overview
9.5.19.2. North Dakota Market Size and Forecast, By Product Type, 2021–2035
9.5.19.3. North Dakota Market Size and Forecast, By Clinical Application, 2021–2035
9.5.19.4. North Dakota Market Size and Forecast, By Technology, 2021–2035
9.5.19.5. North Dakota Market Size and Forecast, By End User, 2021–2035
9.5.20. South Dakota
9.5.20.1. Overview
9.5.20.2. South Dakota Market Size and Forecast, By Product Type, 2021–2035
9.5.20.3. South Dakota Market Size and Forecast, By Clinical Application, 2021–2035
9.5.20.4. South Dakota Market Size and Forecast, By Technology, 2021–2035
9.5.20.5. South Dakota Market Size and Forecast, By End User, 2021–2035

What this section provides: This section delivers granular regional and state-level intelligence across all 50 U.S. states, helping clients identify testing-volume hubs, analyzer-placement opportunities, CLIA-waived adoption hotspots, high-value clinical applications, regional competitive intensity, and priority commercial territories.

10. U.S. Multiplex Point-of-Care Testing Devices Market: Competitive Landscape & Company Profiles

10.1. Market Share Analysis, 2025
10.2. Competitive Benchmarking
10.2.1. Installed Analyzer Base
10.2.2. Multiplex Assay Menu Breadth
10.2.3. Molecular versus Antigen Positioning
10.2.4. Test Turnaround Time
10.2.5. CLIA-Waived Portfolio
10.2.6. Hospital Penetration
10.2.7. Urgent Care and Physician Office Penetration
10.2.8. Connectivity and Digital Capabilities
10.3. Company Positioning Matrix
10.3.1. Market Leaders
10.3.2. Established Challengers
10.3.3. Technology Innovators
10.3.4. Emerging Players
10.4. Competitive Strategy Analysis
10.4.1. Instrument Placement Strategy
10.4.2. Razor-and-Blade Cartridge Revenue Strategy
10.4.3. Menu Expansion Strategy
10.4.4. Health-System Contracting
10.4.5. Urgent Care and Retail Channel Strategy
10.4.6. Partnerships, Licensing and M&A
10.5. Company Profiles
10.5.1. bioMérieux / BioFire Diagnostics
10.5.2. Roche Diagnostics
10.5.3. Cepheid / Danaher Corporation
10.5.4. Abbott Laboratories
10.5.5. QuidelOrtho Corporation
10.5.6. Visby Medical
10.5.7. DiaSorin Molecular
10.5.8. LEX Diagnostics
10.5.9. Nuclein
10.5.10. Baebies
10.5.11. Becton, Dickinson and Company
10.5.12. Thermo Fisher Scientific
10.5.13. Sekisui Diagnostics
10.5.14. ACON Laboratories
10.5.15. Healgen Scientific
10.5.16. Access Bio
10.5.17. Princeton BioMeditech
10.5.18. CorDx
10.5.19. binx health
10.5.20. Lumos Diagnostics
10.5.21. Autonomous Medical Devices
10.5.22. Hologic
10.5.23. Meridian Bioscience
10.5.24. OraSure Technologies
10.5.25. Siemens Healthineers

Note: Each company profile will include company overview, relevant multiplex POC portfolio, U.S. market positioning, key analyzer and assay platforms, regulatory status, CLIA-waived strategy, clinical applications, commercial channel strategy, partnerships, product pipeline, and recent developments.

What this section provides: This section gives clients competitor benchmarking, market-share visibility, platform positioning, analyzer-installed-base intelligence, assay-menu comparison, innovation direction, regulatory positioning, and strategic intelligence on major and emerging U.S. multiplex POC testing competitors.

11. U.S. Multiplex Point-of-Care Testing Devices Market: Future Market Outlook, 2026–2035

11.1. Scenario Analysis
11.1.1. Optimistic Scenario
11.1.2. Base/Realistic Scenario
11.1.3. Pessimistic Scenario
11.2. Disruptive Technologies Impact
11.2.1. Ultra-Rapid Multiplex PCR
11.2.2. Analyzer-Free Molecular Testing
11.2.3. Microfluidic Lab-on-Chip Platforms
11.2.4. Multiplex Digital Immunoassays
11.2.5. Electrochemical Biosensors
11.2.6. Host-Response Diagnostics
11.2.7. AI-Assisted Diagnostic Interpretation
11.3. Future Clinical Menu Expansion
11.3.1. Next-Generation Respiratory Panels
11.3.2. STI Multiplexing
11.3.3. Gastrointestinal Panels
11.3.4. Antimicrobial Resistance Detection
11.3.5. Febrile Illness Panels
11.3.6. Home Multiplex Diagnostics
11.4. Emerging Business Model Trends
11.5. Analyzer Placement versus Direct Instrument Sale Outlook
11.6. Recurring Cartridge Revenue Opportunity
11.7. Business Opportunities for Startups and Existing Players
11.8. Investment Prioritization Matrix
11.9. White-Space Opportunity Analysis

What this section provides: This section prepares clients for technology disruption, diagnostic menu evolution, future business-model changes, competitive shifts, investment opportunities, and adoption scenarios expected to shape the U.S. market through 2035.

12. U.S. Multiplex Point-of-Care Testing Devices Market: Strategic Recommendations

12.1. Recommendations for Multiplex Diagnostic Device Manufacturers
12.2. Recommendations for Hospitals and Integrated Health Systems
12.3. Recommendations for Urgent Care and Retail Health Networks
12.4. Recommendations for Clinical Laboratories and POC Coordinators
12.5. Recommendations for Investors and Private Equity Firms
12.6. Recommendations for Distributors and Channel Partners
12.7. Recommendations for New Entrants and Startups
12.8. U.S. Market Entry Strategy Considerations
12.9. Go-to-Market Strategy
12.9.1. Hospital and IDN Strategy
12.9.2. Urgent Care Network Strategy
12.9.3. Physician Office Strategy
12.9.4. Community Health Strategy
12.9.5. Retail and Consumer Strategy
12.10. Product Positioning and Portfolio Expansion Guidance
12.11. Assay Menu Expansion Priorities
12.12. Pricing and Reimbursement Strategy
12.13. CLIA-Waiver Commercialization Strategy
12.14. Analyzer Placement and Cartridge Utilization Strategy
12.15. Partnership, Licensing and M&A Opportunity Assessment

What this section provides: This section converts market intelligence into actionable recommendations for product development, U.S. commercialization, assay-menu expansion, pricing, reimbursement, channel strategy, analyzer placement, investment planning, and competitive differentiation.

13. U.S. Multiplex Point-of-Care Testing Devices Market: Disclaimer

13.1. Scope Limitation
13.2. Market Definition and Inclusion/Exclusion Limitation
13.3. Data Use Limitation
13.4. Forecasting Limitation
13.5. State-Level Market Estimation Limitation
13.6. Regulatory and Reimbursement Data Limitation
13.7. Legal Disclaimer
13.8. Third-Party Data Disclaimer

What this section provides: This section clarifies the report’s market-scope limitations, state-level modeling assumptions, forecasting constraints, regulatory and reimbursement considerations, legal boundaries, and permitted use of underlying market intelligence.

 

List of Tables

TABLE 1: List of Data Sources
TABLE 2: U.S. Multiplex Point-of-Care Testing Devices Market: Market Definition and Scope
TABLE 3: U.S. Multiplex Point-of-Care Testing Devices Market: Research Methodology Framework
TABLE 4: U.S. Multiplex Point-of-Care Testing Devices Market: Key Assumptions
TABLE 5: U.S. Multiplex Point-of-Care Testing Devices Market: Market Ecosystem Overview
TABLE 6: U.S. Multiplex Point-of-Care Testing Devices Market: Stakeholder Analysis
TABLE 7: U.S. Multiplex Point-of-Care Testing Devices Market: Executive Summary Snapshot, 2025
TABLE 8: U.S. Multiplex Point-of-Care Testing Devices Market: Analyst Viewpoint Summary
TABLE 9: U.S. Multiplex Point-of-Care Testing Devices Market: Market Attractiveness Index
TABLE 10: U.S. Multiplex Point-of-Care Testing Devices Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 11: U.S. Multiplex Point-of-Care Testing Devices Market: Base Year Market Positioning, 2025
TABLE 12: U.S. Multiplex Point-of-Care Testing Devices Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 13: U.S. Multiplex Point-of-Care Testing Devices Market: Year-wise Market Size, 2021–2035 (US$ Billion)
TABLE 14: U.S. Multiplex Point-of-Care Testing Devices Market: High-Growth Opportunity Areas
TABLE 15: U.S. Multiplex Point-of-Care Testing Devices Market: Drivers; Impact Analysis
TABLE 16: U.S. Multiplex Point-of-Care Testing Devices Market: Restraints; Impact Analysis
TABLE 17: U.S. Multiplex Point-of-Care Testing Devices Market: Opportunities; Impact Analysis
TABLE 18: U.S. Multiplex Point-of-Care Testing Devices Market: Challenges; Impact Analysis
TABLE 19: U.S. Multiplex Point-of-Care Testing Devices Market: Patent & Innovation Analysis, 2021–2025
TABLE 20: U.S. Multiplex Point-of-Care Testing Devices Market: Clinical Workflow Economics Matrix
TABLE 21: U.S. Multiplex Point-of-Care Testing Devices Market: Point-of-Care vs Central Laboratory Turnaround-Time Analysis
TABLE 22: U.S. Multiplex Point-of-Care Testing Devices Market: Analyzer Placement and Recurring Cartridge Economics
TABLE 23: U.S. Multiplex Point-of-Care Testing Devices Market: Hospital and Urgent Care Procurement Behavior Matrix
TABLE 24: U.S. Multiplex Point-of-Care Testing Devices Market: PESTEL Analysis
TABLE 25: U.S. Multiplex Point-of-Care Testing Devices Market: Porter’s Five Forces Analysis
TABLE 26: U.S. Multiplex Point-of-Care Testing Devices Market: Pricing Trend Analysis, 2025–2035
TABLE 27: U.S. Multiplex Point-of-Care Testing Devices Market: Analyzer and Cartridge Value Chain Analysis
TABLE 28: U.S. Multiplex Point-of-Care Testing Devices Market: Supply Chain Analysis
TABLE 29: U.S. Multiplex Point-of-Care Testing Devices Market: POC Connectivity and Digitalization Landscape
TABLE 30: U.S. Multiplex Point-of-Care Testing Devices Market: Application & Innovation Landscape
TABLE 31: U.S. Multiplex Point-of-Care Testing Devices Market: FDA Regulatory Framework Analysis
TABLE 32: U.S. Multiplex Point-of-Care Testing Devices Market: CLIA Regulatory and Waiver Landscape
TABLE 33: U.S. Multiplex Point-of-Care Testing Devices Market: CMS Reimbursement and Coverage Landscape
TABLE 34: U.S. Multiplex Point-of-Care Testing Devices Market: CPT Coding and Diagnostic Reimbursement Dynamics
TABLE 35: U.S. Multiplex Point-of-Care Testing Devices Market: Public Health Programs and Federal Initiatives
TABLE 36: U.S. Multiplex Point-of-Care Testing Devices Market: Import/Export Restrictions & Tariff Impact
TABLE 37: U.S. Multiplex Point-of-Care Testing Devices Market: Geopolitical and Supply-Chain Disruption Impact
TABLE 38: U.S. Multiplex Point-of-Care Testing Devices Market: Health-System Value Analysis and Vendor Selection Framework
TABLE 39: U.S. Multiplex Point-of-Care Testing Devices Market: Product Type Snapshot, 2025
TABLE 40: Segment Dashboard; Definition and Scope, by Product Type
TABLE 41: U.S. Multiplex Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 42: U.S. Multiplex Point-of-Care Testing Devices Market: Segment Share Analysis, by Product Type, 2025 & 2035 (%)
TABLE 43: Multiplex Assay Cartridges, Cassettes and Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 44: Multiplex Analyzer Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 45: Software and Connectivity Solutions Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 46: Accessories, Controls and Supporting Components Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 47: U.S. Multiplex Point-of-Care Testing Devices Market: Clinical Application Snapshot, 2025
TABLE 48: Segment Dashboard; Definition and Scope, by Clinical Application
TABLE 49: U.S. Multiplex Point-of-Care Testing Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 50: U.S. Multiplex Point-of-Care Testing Devices Market: Segment Share Analysis, by Clinical Application, 2025 & 2035 (%)
TABLE 51: Respiratory Infectious Disease Testing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 52: Sexual Health and STI Testing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 53: Gastrointestinal and Enteric Disease Testing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 54: Febrile Illness and Host-Response Testing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 55: Other Multiplex Clinical Applications Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 56: U.S. Multiplex Point-of-Care Testing Devices Market: Technology Snapshot, 2025
TABLE 57: Segment Dashboard; Definition and Scope, by Technology
TABLE 58: U.S. Multiplex Point-of-Care Testing Devices Market, by Technology, 2021–2035 (US$ Billion)
TABLE 59: U.S. Multiplex Point-of-Care Testing Devices Market: Segment Share Analysis, by Technology, 2025 & 2035 (%)
TABLE 60: PCR and Real-Time RT-PCR Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 61: Isothermal Nucleic Acid Amplification Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 62: Multiplex Antigen Immunoassays and Lateral Flow Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 63: Microfluidic and Electrochemical Detection Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 64: Emerging Biosensor and Integrated Detection Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 65: U.S. Multiplex Point-of-Care Testing Devices Market: End User Snapshot, 2025
TABLE 66: Segment Dashboard; Definition and Scope, by End User
TABLE 67: U.S. Multiplex Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 68: U.S. Multiplex Point-of-Care Testing Devices Market: Segment Share Analysis, by End User, 2025 & 2035 (%)
TABLE 69: Hospitals and Emergency Departments Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 70: Urgent Care and Retail Healthcare Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 71: Physician Offices and Primary Care Clinics Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 72: Ambulatory, Specialty and Community Clinics Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 73: Home and Consumer-Directed Testing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 74: U.S. Multiplex Point-of-Care Testing Devices Market: Regional Snapshot, 2025
TABLE 75: Segment Dashboard; Definition and Scope, by Geography
TABLE 76: U.S. Multiplex Point-of-Care Testing Devices Market, by Region, 2021–2035 (US$ Billion)
TABLE 77: U.S. Multiplex Point-of-Care Testing Devices Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 78: U.S. Multiplex Point-of-Care Testing Devices Market: Regional Infectious Disease Testing Burden
TABLE 79: U.S. Multiplex Point-of-Care Testing Devices Market: Regional Hospital and Urgent Care Infrastructure
TABLE 80: U.S. Multiplex Point-of-Care Testing Devices Market: Regional CLIA-Waived Testing Adoption
TABLE 81: West Region U.S. Multiplex Point-of-Care Testing Devices Market: Regional Overview and Trends
TABLE 82: West Region U.S. Multiplex Point-of-Care Testing Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 83: West Region U.S. Multiplex Point-of-Care Testing Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 84: West Region Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 85: West Region Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 86: West Region Market, by Technology, 2021–2035 (US$ Billion)
TABLE 87: West Region Market, by End User, 2021–2035 (US$ Billion)
TABLE 88: West Region Testing Volume, Installed Base and Adoption Hotspot Analysis
TABLE 89: California Multiplex Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 90: Washington Multiplex Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 91: Arizona Multiplex Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 92: Colorado Multiplex Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 93: Oregon Multiplex Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 94: Utah Multiplex Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 95: Nevada Multiplex Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 96: New Mexico Multiplex Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 97: Idaho Multiplex Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 98: Montana Multiplex Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 99: Wyoming Multiplex Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 100: Alaska Multiplex Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 101: Hawaii Multiplex Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 102: Northeast Region U.S. Multiplex Point-of-Care Testing Devices Market: Regional Overview and Trends
TABLE 103: Northeast Region U.S. Multiplex Point-of-Care Testing Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 104: Northeast Region U.S. Multiplex Point-of-Care Testing Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 105: Northeast Region Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 106: Northeast Region Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 107: Northeast Region Market, by Technology, 2021–2035 (US$ Billion)
TABLE 108: Northeast Region Market, by End User, 2021–2035 (US$ Billion)
TABLE 109: Northeast Region Testing Volume, Installed Base and Adoption Hotspot Analysis
TABLE 110: New York Multiplex Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 111: Massachusetts Multiplex Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 112: New Jersey Multiplex Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 113: Pennsylvania Multiplex Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 114: Connecticut Multiplex Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 115: Maine Multiplex Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 116: Vermont Multiplex Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 117: New Hampshire Multiplex Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 118: Rhode Island Multiplex Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 119: Delaware Multiplex Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 120: South Region U.S. Multiplex Point-of-Care Testing Devices Market: Regional Overview and Trends
TABLE 121: South Region U.S. Multiplex Point-of-Care Testing Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 122: South Region U.S. Multiplex Point-of-Care Testing Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 123: South Region Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 124: South Region Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 125: South Region Market, by Technology, 2021–2035 (US$ Billion)
TABLE 126: South Region Market, by End User, 2021–2035 (US$ Billion)
TABLE 127: South Region Testing Volume, Installed Base and Adoption Hotspot Analysis
TABLE 128: Texas Multiplex Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 129: Florida Multiplex Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 130: Georgia Multiplex Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 131: North Carolina Multiplex Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 132: Tennessee Multiplex Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 133: South Carolina Multiplex Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 134: Alabama Multiplex Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 135: Mississippi Multiplex Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 136: Louisiana Multiplex Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 137: Arkansas Multiplex Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 138: Kentucky Multiplex Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 139: Oklahoma Multiplex Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 140: Virginia Multiplex Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 141: Maryland Multiplex Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 142: West Virginia Multiplex Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 143: Midwest Region U.S. Multiplex Point-of-Care Testing Devices Market: Regional Overview and Trends
TABLE 144: Midwest Region U.S. Multiplex Point-of-Care Testing Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 145: Midwest Region U.S. Multiplex Point-of-Care Testing Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 146: Midwest Region Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 147: Midwest Region Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 148: Midwest Region Market, by Technology, 2021–2035 (US$ Billion)
TABLE 149: Midwest Region Market, by End User, 2021–2035 (US$ Billion)
TABLE 150: Midwest Region Testing Volume, Installed Base and Adoption Hotspot Analysis
TABLE 151: Illinois Multiplex Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 152: Ohio Multiplex Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 153: Michigan Multiplex Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 154: Minnesota Multiplex Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 155: Indiana Multiplex Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 156: Wisconsin Multiplex Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 157: Missouri Multiplex Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 158: Iowa Multiplex Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 159: Kansas Multiplex Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 160: Nebraska Multiplex Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 161: North Dakota Multiplex Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 162: South Dakota Multiplex Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 163: U.S. Multiplex Point-of-Care Testing Devices Market: Competitive Landscape Snapshot, 2025
TABLE 164: U.S. Multiplex Point-of-Care Testing Devices Market: Key Company Market Share Analysis, 2025
TABLE 165: U.S. Multiplex Point-of-Care Testing Devices Market: Competitive Benchmarking Matrix
TABLE 166: U.S. Multiplex Point-of-Care Testing Devices Market: Company Positioning Matrix
TABLE 167: U.S. Multiplex Point-of-Care Testing Devices Market: Analyzer and Assay Portfolio Benchmarking
TABLE 168: U.S. Multiplex Point-of-Care Testing Devices Market: CLIA-Waived Portfolio Benchmarking
TABLE 169: U.S. Multiplex Point-of-Care Testing Devices Market: Strategic Developments, Partnerships, M&A and Product Launches
TABLE 170: bioMérieux / BioFire Diagnostics: Company Profile
TABLE 171: Roche Diagnostics: Company Profile
TABLE 172: Cepheid / Danaher Corporation: Company Profile
TABLE 173: Abbott Laboratories: Company Profile
TABLE 174: QuidelOrtho Corporation: Company Profile
TABLE 175: Visby Medical: Company Profile
TABLE 176: DiaSorin Molecular: Company Profile
TABLE 177: LEX Diagnostics: Company Profile
TABLE 178: Nuclein: Company Profile
TABLE 179: Baebies: Company Profile
TABLE 180: Becton, Dickinson and Company: Company Profile
TABLE 181: Thermo Fisher Scientific: Company Profile
TABLE 182: Sekisui Diagnostics: Company Profile
TABLE 183: ACON Laboratories: Company Profile
TABLE 184: Healgen Scientific: Company Profile
TABLE 185: Access Bio: Company Profile
TABLE 186: Princeton BioMeditech: Company Profile
TABLE 187: CorDx: Company Profile
TABLE 188: binx health: Company Profile
TABLE 189: Lumos Diagnostics: Company Profile
TABLE 190: Autonomous Medical Devices: Company Profile
TABLE 191: Hologic: Company Profile
TABLE 192: Meridian Bioscience: Company Profile
TABLE 193: OraSure Technologies: Company Profile
TABLE 194: Siemens Healthineers: Company Profile
TABLE 195: U.S. Multiplex Point-of-Care Testing Devices Market: Future Market Scenario Analysis, 2026–2035
TABLE 196: U.S. Multiplex Point-of-Care Testing Devices Market: Disruptive Technologies Impact Matrix
TABLE 197: U.S. Multiplex Point-of-Care Testing Devices Market: Future Clinical Menu Expansion Matrix
TABLE 198: U.S. Multiplex Point-of-Care Testing Devices Market: Emerging Business Model Trends
TABLE 199: U.S. Multiplex Point-of-Care Testing Devices Market: Analyzer Placement vs Direct Instrument Sale Outlook
TABLE 200: U.S. Multiplex Point-of-Care Testing Devices Market: Recurring Cartridge Revenue Opportunity
TABLE 201: U.S. Multiplex Point-of-Care Testing Devices Market: Business Opportunities for Startups and Existing Players
TABLE 202: U.S. Multiplex Point-of-Care Testing Devices Market: Investment Prioritization Matrix
TABLE 203: U.S. Multiplex Point-of-Care Testing Devices Market: White-Space Opportunity Analysis
TABLE 204: U.S. Multiplex Point-of-Care Testing Devices Market: Strategic Recommendations for Diagnostic Device Manufacturers
TABLE 205: U.S. Multiplex Point-of-Care Testing Devices Market: Strategic Recommendations for Hospitals and Health Systems
TABLE 206: U.S. Multiplex Point-of-Care Testing Devices Market: Strategic Recommendations for Urgent Care and Retail Health Networks
TABLE 207: U.S. Multiplex Point-of-Care Testing Devices Market: Strategic Recommendations for Clinical Laboratories and POC Coordinators
TABLE 208: U.S. Multiplex Point-of-Care Testing Devices Market: Strategic Recommendations for Investors and Private Equity Firms
TABLE 209: U.S. Multiplex Point-of-Care Testing Devices Market: Strategic Recommendations for Distributors and Channel Partners
TABLE 210: U.S. Multiplex Point-of-Care Testing Devices Market: Strategic Recommendations for New Entrants and Startups
TABLE 211: U.S. Multiplex Point-of-Care Testing Devices Market: U.S. Market Entry Strategy
TABLE 212: U.S. Multiplex Point-of-Care Testing Devices Market: Go-to-Market Strategy Framework
TABLE 213: U.S. Multiplex Point-of-Care Testing Devices Market: Product Positioning and Portfolio Expansion Guidance
TABLE 214: U.S. Multiplex Point-of-Care Testing Devices Market: Assay Menu Expansion Priorities
TABLE 215: U.S. Multiplex Point-of-Care Testing Devices Market: Pricing and Reimbursement Strategy
TABLE 216: U.S. Multiplex Point-of-Care Testing Devices Market: CLIA-Waiver Commercialization Strategy
TABLE 217: U.S. Multiplex Point-of-Care Testing Devices Market: Analyzer Placement and Cartridge Utilization Strategy
TABLE 218: U.S. Multiplex Point-of-Care Testing Devices Market: Partnership, Licensing and M&A Opportunity Assessment
TABLE 219: U.S. Multiplex Point-of-Care Testing Devices Market: Scope Limitation
TABLE 220: U.S. Multiplex Point-of-Care Testing Devices Market: Market Definition and Inclusion/Exclusion Limitation
TABLE 221: U.S. Multiplex Point-of-Care Testing Devices Market: Data Use Limitation
TABLE 222: U.S. Multiplex Point-of-Care Testing Devices Market: Forecasting Limitation
TABLE 223: U.S. Multiplex Point-of-Care Testing Devices Market: State-Level Market Estimation Limitation
TABLE 224: U.S. Multiplex Point-of-Care Testing Devices Market: Regulatory and Reimbursement Data Limitation
TABLE 225: U.S. Multiplex Point-of-Care Testing Devices Market: Legal Disclaimer
TABLE 226: U.S. Multiplex Point-of-Care Testing Devices Market: Third-Party Data Disclaimer

List of Figures

FIGURE 1: U.S. Multiplex Point-of-Care Testing Devices Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: Market Ecosystem and Stakeholder Framework
FIGURE 4: Market Attractiveness Analysis
FIGURE 5: U.S. Multiplex Point-of-Care Testing Devices Market Historical Trend, 2021–2024 (US$ Billion)
FIGURE 6: U.S. Multiplex Point-of-Care Testing Devices Market Forecast and Trend Analysis, 2026–2035 (US$ Billion)
FIGURE 7: U.S. Multiplex Point-of-Care Testing Devices Market Year-wise Growth Curve, 2021–2035
FIGURE 8: High-Growth Opportunity Heatmap
FIGURE 9: Market Dynamics
FIGURE 10: Innovation & Patent Landscape, 2021–2025
FIGURE 11: Clinical Workflow Economics Framework
FIGURE 12: Point-of-Care vs Central Laboratory Diagnostic Workflow
FIGURE 13: Analyzer Placement and Recurring Cartridge Revenue Model
FIGURE 14: Hospital and Urgent Care Procurement Decision Framework
FIGURE 15: PESTEL Analysis
FIGURE 16: Porter’s Five Forces Analysis
FIGURE 17: Analyzer and Cartridge Value Chain Analysis
FIGURE 18: Supply Chain Analysis
FIGURE 19: FDA, CLIA and Reimbursement Framework
FIGURE 20: Product Type Segment Market Share Analysis, 2025 & 2035
FIGURE 21: Product Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 22: Multiplex Assay Cartridges, Cassettes and Test Kits Market Trend, 2021–2035
FIGURE 23: Multiplex Analyzer Systems Market Trend, 2021–2035
FIGURE 24: Software and Connectivity Solutions Market Trend, 2021–2035
FIGURE 25: Clinical Application Segment Market Share Analysis, 2025 & 2035
FIGURE 26: Clinical Application Segment Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 27: Respiratory Infectious Disease Testing Market Trend, 2021–2035
FIGURE 28: Sexual Health and STI Testing Market Trend, 2021–2035
FIGURE 29: Gastrointestinal and Enteric Testing Market Trend, 2021–2035
FIGURE 30: Febrile Illness and Host-Response Testing Market Trend, 2021–2035
FIGURE 31: Technology Segment Market Share Analysis, 2025 & 2035
FIGURE 32: Technology Segment Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 33: PCR and Real-Time RT-PCR Market Trend, 2021–2035
FIGURE 34: Isothermal Molecular Amplification Market Trend, 2021–2035
FIGURE 35: Multiplex Antigen Immunoassay and Lateral Flow Market Trend, 2021–2035
FIGURE 36: Microfluidic and Electrochemical Detection Market Trend, 2021–2035
FIGURE 37: Emerging Biosensor and Integrated Detection Technology Roadmap
FIGURE 38: End User Segment Market Share Analysis, 2025 & 2035
FIGURE 39: End User Segment Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 40: Hospitals and Emergency Departments Market Trend, 2021–2035
FIGURE 41: Urgent Care and Retail Healthcare Market Trend, 2021–2035
FIGURE 42: Physician Offices and Primary Care Clinics Market Trend, 2021–2035
FIGURE 43: Ambulatory, Specialty and Community Clinics Market Trend, 2021–2035
FIGURE 44: Home and Consumer-Directed Multiplex Testing Market Trend, 2021–2035
FIGURE 45: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 46: Regional Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 47: Regional Infectious Disease Testing Burden and POC Adoption Map
FIGURE 48: West Region Market Share and Leading Players, 2025
FIGURE 49: West Region Market Share Analysis by State, 2025
FIGURE 50: West Region Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 51: California Multiplex Point-of-Care Testing Devices Market Trend, 2021–2035
FIGURE 52: Washington Multiplex Point-of-Care Testing Devices Market Trend, 2021–2035
FIGURE 53: Arizona Multiplex Point-of-Care Testing Devices Market Trend, 2021–2035
FIGURE 54: Colorado Multiplex Point-of-Care Testing Devices Market Trend, 2021–2035
FIGURE 55: Oregon Multiplex Point-of-Care Testing Devices Market Trend, 2021–2035
FIGURE 56: Utah Multiplex Point-of-Care Testing Devices Market Trend, 2021–2035
FIGURE 57: Nevada Multiplex Point-of-Care Testing Devices Market Trend, 2021–2035
FIGURE 58: New Mexico Multiplex Point-of-Care Testing Devices Market Trend, 2021–2035
FIGURE 59: Idaho Multiplex Point-of-Care Testing Devices Market Trend, 2021–2035
FIGURE 60: Montana Multiplex Point-of-Care Testing Devices Market Trend, 2021–2035
FIGURE 61: Wyoming Multiplex Point-of-Care Testing Devices Market Trend, 2021–2035
FIGURE 62: Alaska Multiplex Point-of-Care Testing Devices Market Trend, 2021–2035
FIGURE 63: Hawaii Multiplex Point-of-Care Testing Devices Market Trend, 2021–2035
FIGURE 64: Northeast Region Market Share and Leading Players, 2025
FIGURE 65: Northeast Region Market Share Analysis by State, 2025
FIGURE 66: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 67: New York Multiplex Point-of-Care Testing Devices Market Trend, 2021–2035
FIGURE 68: Massachusetts Multiplex Point-of-Care Testing Devices Market Trend, 2021–2035
FIGURE 69: New Jersey Multiplex Point-of-Care Testing Devices Market Trend, 2021–2035
FIGURE 70: Pennsylvania Multiplex Point-of-Care Testing Devices Market Trend, 2021–2035
FIGURE 71: Connecticut Multiplex Point-of-Care Testing Devices Market Trend, 2021–2035
FIGURE 72: Maine Multiplex Point-of-Care Testing Devices Market Trend, 2021–2035
FIGURE 73: Vermont Multiplex Point-of-Care Testing Devices Market Trend, 2021–2035
FIGURE 74: New Hampshire Multiplex Point-of-Care Testing Devices Market Trend, 2021–2035
FIGURE 75: Rhode Island Multiplex Point-of-Care Testing Devices Market Trend, 2021–2035
FIGURE 76: Delaware Multiplex Point-of-Care Testing Devices Market Trend, 2021–2035
FIGURE 77: South Region Market Share and Leading Players, 2025
FIGURE 78: South Region Market Share Analysis by State, 2025
FIGURE 79: South Region Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 80: Texas Multiplex Point-of-Care Testing Devices Market Trend, 2021–2035
FIGURE 81: Florida Multiplex Point-of-Care Testing Devices Market Trend, 2021–2035
FIGURE 82: Georgia Multiplex Point-of-Care Testing Devices Market Trend, 2021–2035
FIGURE 83: North Carolina Multiplex Point-of-Care Testing Devices Market Trend, 2021–2035
FIGURE 84: Tennessee Multiplex Point-of-Care Testing Devices Market Trend, 2021–2035
FIGURE 85: South Carolina Multiplex Point-of-Care Testing Devices Market Trend, 2021–2035
FIGURE 86: Alabama Multiplex Point-of-Care Testing Devices Market Trend, 2021–2035
FIGURE 87: Mississippi Multiplex Point-of-Care Testing Devices Market Trend, 2021–2035
FIGURE 88: Louisiana Multiplex Point-of-Care Testing Devices Market Trend, 2021–2035
FIGURE 89: Arkansas Multiplex Point-of-Care Testing Devices Market Trend, 2021–2035
FIGURE 90: Kentucky Multiplex Point-of-Care Testing Devices Market Trend, 2021–2035
FIGURE 91: Oklahoma Multiplex Point-of-Care Testing Devices Market Trend, 2021–2035
FIGURE 92: Virginia Multiplex Point-of-Care Testing Devices Market Trend, 2021–2035
FIGURE 93: Maryland Multiplex Point-of-Care Testing Devices Market Trend, 2021–2035
FIGURE 94: West Virginia Multiplex Point-of-Care Testing Devices Market Trend, 2021–2035
FIGURE 95: Midwest Region Market Share and Leading Players, 2025
FIGURE 96: Midwest Region Market Share Analysis by State, 2025
FIGURE 97: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 98: Illinois Multiplex Point-of-Care Testing Devices Market Trend, 2021–2035
FIGURE 99: Ohio Multiplex Point-of-Care Testing Devices Market Trend, 2021–2035
FIGURE 100: Michigan Multiplex Point-of-Care Testing Devices Market Trend, 2021–2035
FIGURE 101: Minnesota Multiplex Point-of-Care Testing Devices Market Trend, 2021–2035
FIGURE 102: Indiana Multiplex Point-of-Care Testing Devices Market Trend, 2021–2035
FIGURE 103: Wisconsin Multiplex Point-of-Care Testing Devices Market Trend, 2021–2035
FIGURE 104: Missouri Multiplex Point-of-Care Testing Devices Market Trend, 2021–2035
FIGURE 105: Iowa Multiplex Point-of-Care Testing Devices Market Trend, 2021–2035
FIGURE 106: Kansas Multiplex Point-of-Care Testing Devices Market Trend, 2021–2035
FIGURE 107: Nebraska Multiplex Point-of-Care Testing Devices Market Trend, 2021–2035
FIGURE 108: North Dakota Multiplex Point-of-Care Testing Devices Market Trend, 2021–2035
FIGURE 109: South Dakota Multiplex Point-of-Care Testing Devices Market Trend, 2021–2035
FIGURE 110: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 111: Company Positioning Matrix
FIGURE 112: Analyzer and Multiplex Assay Portfolio Benchmarking
FIGURE 113: CLIA-Waived Competitive Positioning Matrix
FIGURE 114: Strategic Developments, Partnerships, M&A and Product Launches
FIGURE 115: Multiplex Point-of-Care Testing Innovation Roadmap
FIGURE 116: Ultra-Rapid Multiplex PCR Adoption Roadmap
FIGURE 117: Analyzer-Free Molecular Testing Opportunity Map
FIGURE 118: Respiratory Multiplex Testing Evolution Roadmap
FIGURE 119: Sexual Health Multiplex Testing Growth Roadmap
FIGURE 120: Future Clinical Menu Expansion Framework
FIGURE 121: Future Market Scenario Analysis, 2026–2035
FIGURE 122: Disruptive Technologies Impact Matrix
FIGURE 123: Emerging Business Model Trends Matrix
FIGURE 124: Recurring Cartridge Revenue Opportunity Framework
FIGURE 125: Investment Prioritization Matrix
FIGURE 126: White-Space Opportunity Map
FIGURE 127: Strategic Growth Roadmap for U.S. Multiplex POC Testing Companies
FIGURE 128: U.S. Market Entry and Go-to-Market Strategy Framework
FIGURE 129: Product Positioning and Portfolio Expansion Framework
FIGURE 130: Assay Menu Expansion Priority Matrix
FIGURE 131: Pricing, Reimbursement and CLIA-Waiver Commercialization Framework
FIGURE 132: Analyzer Placement and Cartridge Utilization Strategy
FIGURE 133: Partnership, Licensing and M&A Opportunity Framework
FIGURE 134: Report Scope and Disclaimer Framework